Document:

EX-10.18

 Exhibit 10.18 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 
 LICENSE AGREEMENT 

This License Agreement (this “Agreement”), dated as of June __, 2018 (the “Effective Date”),
is made by and between Aerpio Pharmaceuticals, Inc., a Delaware corporation having business offices at 9987 Carver Road, Suite 420, Cincinnati, OH 45254 (“Aerpio”), and GB004, Inc., a Delaware corporation having business offices at
3013 Science Park Road, Suite 200, San Diego, CA 92121 (“Licensee”). Aerpio and Licensee are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.” 

WHEREAS, Aerpio has been engaged in the development of AKB-4924, a compound that binds to HIF prolyl
hydroxylase resulting in HIF stabilization, and controls certain patent rights and know-how with respect thereto; 

WHEREAS, Licensee desires to obtain exclusive rights under the Aerpio Patent Rights and Aerpio
Know-How in order to continue the development thereof and products containing same; and 
 WHEREAS,
the Parties desire to enter into an agreement pursuant to which Aerpio will grant an exclusive license to Licensee under the Aerpio Patent Rights and Aerpio Know-How for Licensee to develop, manufacture and
commercialize the Licensed Compound and Licensed Products for initially the indications of induction and maintenance in ulcerative colitis and the induction and maintenance in Crohn’s Disease, all on the terms set forth below. 

NOW, THEREFORE, the Parties hereby agree as follows: 

Section 1. Definitions. 
 For the
purpose of this Agreement, the following terms and phrases (and cognates) will have the meanings set forth below: 
 1.1 “Accounting
Standards” means generally accepted accounting principles as practiced in the United States or IFRS (International Financial Reporting Standards), in each case, consistently applied. 

1.2 “Aerpio In-License” means the
Non-Exclusive License Agreement by and between Aerpio and The Regents of the University of Colorado (the “UC Regents”), dated November 1, 2016, as amended or restated from time to
time. A copy of the Aerpio In-License is attached hereto as Exhibit F. 
 1.3 “Aerpio Know-How” means all Know-How, existing as of the Effective Date or disclosed by Aerpio to the Licensee during Term, Controlled by Aerpio or any of its Affiliates,
that is necessary or useful for the research, manufacture, use, sale, offer for sale, importation, development or commercialization of the Licensed Compound or any Licensed Products for use in the Territory in the Field. 

1.4 “Aerpio Patent Rights” means (a) the patents and patent applications listed in Exhibit A attached hereto and any
other patents, patent applications and other patent rights, Controlled by Aerpio or any of its Affiliates, that Cover any Aerpio Know-How, plus (i) all divisionals, continuations, continuations-in-part thereof or any other patent rights claiming priority directly or indirectly to any of the patents or patent applications identified on Exhibit A,
and (ii) all patents issuing on any of the foregoing, together with all registrations, re-issues, re-examinations, renewals, supplemental protection certificates
and extensions of any of the foregoing, and all foreign counterparts thereof (under this clause (a), collectively, the “Aerpio Core Patent Rights”), (b) any other patents, patent applications and other patent rights,
existing as of the Effective Date, Controlled by Aerpio or any of its Affiliates, that are necessary for the manufacture, use, sale, offer for sale or importation of the Licensed Compound or Licensed Products for use in the Territory in the Field.

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 
 1.5
“Affiliate” of a person or entity means any other person or entity which (directly or indirectly) is controlled by, controls or is under common control with such first person or entity. For the purposes of this definition, the
term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect to any entity means (a) in the case of a corporate entity, direct
or indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors or (b) in the case of a non-corporate entity, direct or indirect
ownership of at least fifty percent (50%), including ownership by trusts with substantially the same beneficial interest, of the equity interests with the power to direct the management and policies of such entity, provided that if local law
restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 

1.6 “Change of Control” means with respect to a Party, in one transaction or a series of related transactions, the merger,
consolidation, reorganization, business combination, sale of all (or substantially all) of the capital stock (or other equity interests) or assets, the change in voting control (that is, when the equity or other security holders of such Party or
Affiliate immediately preceding such transaction(s) hold less than fifty percent (50%) of the outstanding equity or other securities, or less than fifty percent (50%) of the outstanding voting power, respectively, of the ultimate company or entity
resulting from such transaction(s) immediately after consummation thereof), liquidation or dissolution, the license, sublicense, sale, assignment or other transfer of all or substantially all of such Party’s business or assets to which this
Agreement relates, or any other form of acquisition or liquidity event for such Party. 
 1.7 “Commercially Reasonable
Efforts” means, with respect to the Licensed Compound or any Licensed Product, that level of efforts and resources commonly dedicated in the pharmaceutical industry by [***]. 

1.8 “Commercialization Budget” means the budget for conducting commercialization of any Licensed Product for use in the
Territory and in the Field pursuant to the Commercialization Plan during a given calendar year and [***]. 
 1.9 “Commercialization
Plan” means the plan setting forth the activities and timelines relating to the commercialization (and related manufacturing) of any Licensed Product for use in the Territory and in the Field during a given calendar year and the [***],
including the Commercialization Budget and annual Net Sales forecasts for the Territory. 
 1.10 “Competitive Infringement”
means any allegedly infringing activity with respect to an Aerpio Core Patent Right, which activity (i) falls within the scope then in effect of the license granted by Aerpio to Licensee in Section 5.1(a) and (ii) is reasonably
expected to reduce the Net Sales of any Licensed Product then being commercialized. 
 1.11 “Confidential Information” means
all non-public Know-How, marketing plans, strategies and customer lists, and other non-public information or material that are
disclosed or provided by a Party or its Affiliates to the other Party or its Affiliates, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other by the
disclosing Party or its Affiliates in oral, written, graphic, or electronic form. 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 2 

 1.12 “Confidentiality Agreement” means that certain Bilateral Confidential
and Non-Disclosure Agreement, dated August 4, 2017, by and between Aerpio and Licensee d/b/a FSG Bio Inc. 

1.13 “Control” or “Controlled” means, with respect to any patent right,
Know-How, or other intellectual property right, the possession (whether by ownership or license, other than by a license or sublicense granted pursuant to this Agreement) by a Party or its Affiliates of the
ability to grant to the other Party a license or access as provided herein to such item, without violating the terms of any agreement or other arrangement with any Third Party or, except for the Aerpio
In-License or any patents or patent applications or other intellectual property Covering Aerpio Know-How, being obligated to pay any royalties or other consideration
therefor, in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license or access. 

1.14 “Cover”, “Covered” or “Covering” means, with respect to a particular compound, product
or service and a particular issued patent or patent application, that, but for rights granted hereunder, the making, using, importing, offering for sale or selling of such product or service would infringe a Valid Claim in such patent (or patent
application, as if such claim has issued). 
 1.15 “Development Budget” means a budget for conducting development pursuant
to each Development Plan (a) during a given calendar year and [***] and (b) an overall estimate of the budget required for obtaining a first Regulatory Approval of a first Licensed
Product for the Indication of such Development Plan. 
 1.16 “Development Plan(s)” means, on an Indication-by-Indication basis, the plan setting forth the activities and timelines relating to the development (and related manufacturing) of the Licensed Compound and
Licensed Products in all countries of the Territory for such Indication. An initial draft of each Development Plan for the each of the Initial Indications, as well as any other Indications contemplated for use in the Territory as of the Effective
Date, is set forth on Exhibit B-1. 
 1.17 “EMA” means the European Medicines
Agency and any successor agency thereto. 
 1.18 “European Union” or “EU” means the countries of the
European Economic Area, as it is constituted on the Effective Date, and as it may be expanded from time to time after the Effective Date. 

1.19 “Executive Officers” means (a) for Aerpio, the Chief Executive Officer (or a senior executive officer of Aerpio
designated by the Chief Executive Officer), and (b) for Licensee, the Chief Executive Officer of Licensee. In the event that the position of any of the Executive Officers identified in this Section 1.19 no longer exists due to a corporate
reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable Executive Officer will be replaced with another executive officer with responsibilities and seniority comparable to the
eliminated Executive Officer. 
 1.20 “FD&C Act” means the United States Federal Food, Drug and Cosmetic Act, as
amended. 
 1.21 “FDA” means the United States Food and Drug Administration or any successor agency thereto. 

1.22 “Field” means all applications. 

1.23 “First Commercial Sale” means, with respect to any Licensed Product in a given country or region in the Territory, the
first sale of such Licensed Product in such country or region (whether or not any pricing or reimbursement approvals or decisions have occurred); provided that sales for clinical studies purposes or compassionate or similar use will not be
considered to constitute a First Commercial Sale. For clarity, First Commercial Sale will be determined on a Licensed Product-by-Licensed Product and country-by-country (or region-by-region) basis, as applicable. 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 3 

 1.24 “Generic Product” means, with respect to a particular Licensed Product
in a country, a generic pharmaceutical product that: (a) contains the same active ingredient as the Licensed Compound in the same chemical form as in such Licensed Product; and (b) is approved for use in such country by a Regulatory
Authority through an Abbreviated New Drug Application as defined in the FD&C Act, pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001, or any enabling legislation thereof, or pursuant
to any similar abbreviated route of approval in any other countries in the Territory; or (c) (i) contains the same active ingredient as the Licensed Compound in such Licensed Product; and (ii) is approved for use in such country by a
Regulatory Authority through a regulatory pathway referencing clinical data first submitted by Licensee or its Affiliates or Sublicensees for obtaining Regulatory Approval for such Licensed Product. 

1.25 “Governmental Authority” means any United States federal, state or local or any foreign government, or political
subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or
tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 
 1.26 “IND”
means an Investigational New Drug application, clinical study application, clinical trial exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in
conformance with the requirements of such Regulatory Authority. 
 1.27 “Indication” means an application for a label or
label expansion indicating the applicable drug for an initial, expanded or additional patient population, or indicating the drug for use in combination with another treatment or drug, in each case that requires a new Pivotal Clinical Trial for
Regulatory Approval for such label or label expansion. It is understood and agreed that, notwithstanding anything herein to the contrary, each of the Initial Indications will be treated as separate Indications hereunder for all purposes. 

1.28 “Initial Indications” means each of the following Indications: (i) induction and maintenance in ulcerative colitis
(or similar Indication solely related to inflammatory bowel disease (“IBD”)), (ii) induction and maintenance in Crohn’s Disease (or similar Indication solely related to IBD), and (iii) any other Indication for which a
Development Plan is attached to this Agreement as of the Effective Date. 
 1.29
“Know-How” means know-how, trade secrets, chemical and biological materials, formulations, information, documents, studies, results, data and regulatory
approvals, data (including from clinical studies), filings and correspondence, including biological, chemical, pharmacological, toxicological, pre-clinical, clinical and assay data, manufacturing processes and
data, specifications, sourcing information, assays, and quality control and testing procedures, whether or not patented or patentable. 

1.30 “Law” means any federal, state, provincial, local, international or multinational law, statute, standard, ordinance,
code, rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with any Governmental Authority, or any license, franchise, permit or similar right
granted under any of the foregoing, or any similar provision having the force or effect of law. 
 1.31 “Licensed Compound”
means the compound known as AKB-4924, as further described on Exhibit C, and any solvates (including hydrates), salts, prodrugs, metabolites, acid forms, base forms, polymorphs and crystalline forms
thereof. 
 1.32 “Licensed Product” means any pharmaceutical product containing either (a) the Licensed Compound or
(b) any other compound that is an active pharmaceutical ingredient whose composition of 

  
 4 

 
matter is Covered by the Aerpio Core Patent Rights in each case ((a) and (b)), alone or with other active ingredients, and in all forms, presentations, formulations and dosage forms. 

1.33 “Licensee Patent Rights” means all patents, patent applications and other patent rights, existing as of the Effective
Date or arising during the Term, owned or in-licensed by Licensee or any of its Affiliates as of the Effective Date or during the Term, that have a Valid Claim directed to and Covering [***]. 

1.34 “MAA” means (a) a marketing authorization application filed with (i) the EMA under the centralized EMA filing
procedure or (ii) a Regulatory Authority in any country of the EU if the centralized EMA filing procedure is not used or (b) any other equivalent or related regulatory submission, in either case to gain approval to market a Licensed
Product in any country in the European Union, in each case including, for clarity, amendments thereto and supplemental applications. 
 1.35
“Major European Country” means any of the United Kingdom, France, Germany, Italy or Spain. 
 1.36 “NDA”
means a New Drug Application filed with the FDA (including amendments and supplements thereto) to obtain Regulatory Approval in the United States, or any corresponding applications or submissions filed with the relevant Regulatory Authorities to
obtain Regulatory Approvals in any other country or region in the Territory (including any MAA). 
 1.37 “Net Sales” means,
with respect to any Licensed Product, the gross amounts invoiced on sales of such Licensed Product by Licensee or any of its Affiliates or Sublicensees to a Third Party, less the following customary deductions, determined in accordance with the
Accounting Standards, to the extent specifically and solely allocated to the sale of such Licensed Product and actually taken, paid, accrued, allowed, or included in the gross sales prices with respect to such sales: 

(a) [***]; 
 (b) [***]; 

(c) [***]; 
 (d) [***]; 

(e) [***]; and 
 (f) [***]. 

1.38 “Patent Challenge” means any challenge to the patentability, validity or enforceability of any of the Aerpio Patent
Rights (or any claim thereof), including by: (a) filing or pursuing a declaratory judgment action in which any of the Aerpio Patent Rights is alleged to be invalid or unenforceable; (b) citing prior art against any of the Aerpio Patent
Rights, filing a request for or pursuing a re-examination of any of the Aerpio Patent Rights, or becoming a party to or pursuing an interference; or (c) filing or pursuing any re-examination, opposition, cancellation, nullity or other like proceedings against any of the Aerpio Patent Rights. Notwithstanding the foregoing, any of the following situations shall not be deemed to be a Patent
Challenge: (i) any proceeding involving any Aerpio Patent Rights where Licensee, an Affiliate or Sublicensee has been compelled to participate in, or has been involuntarily drawn into, the proceeding by a court, patent office or third party,
(ii) routine patent office prosecution where Licensee, an Affiliate or Sublicensee is prosecuting its own patent rights, and (iii) any situation where Aerpio or its Affiliates assert or file a patent infringement action against Licensee,
an Affiliate or Sublicensee under any Aerpio Patent Right outside of the scope of the license grant set forth in Section 5.1(a). 
 1.39
“Phase 1 Clinical Trial” means a human clinical trial of a Licensed Product that would satisfy the requirements of 21 C.F.R. § 312.21(a), or a comparable clinical study prescribed by the relevant Regulatory Authority
in a country other than the United States. 
 1.40 “Phase 2 Clinical Trial” means a human clinical trial of a Licensed
Product that would satisfy the requirements of 21 C.F.R. § 312.21(b), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 5 

 1.41 “Phase 3 Clinical Trial” means a human clinical trial of a Licensed
Product that would satisfy the requirements of 21 C.F.R. § 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. 

1.42 “Pivotal Clinical Trial” means a human clinical trial of a Licensed Product (a) intended to establish that such
Licensed Product is safe and effective for its intended use and (b) intended to be sufficient for filing for a Regulatory Approval for such Licensed Product in patients having the disease or condition being studied, solely as evidenced by the
acceptance for filing for a Regulatory Approval for such Licensed Product after completion of such clinical trial. For clarity, a Pivotal Clinical Trial is often referred to as a “label enabling” trial. 

1.43 “Program Transaction” means a (a) Change of Control of Licensee or (b) Subsidiary/Parent Sale, excluding in
each case an initial public offering of Licensee or its Affiliate, as applicable. 
 1.44 “Prosecute”,
“Prosecution” or “Prosecuting” means with respect to any patent rights, (a) to prepare and file patent applications, including re-examinations or re-issues thereof, and represent applicants or assignees before relevant patent offices or other relevant Governmental Authorities during examination, re-examination and re-issue thereof, in appeal processes and interferences, or any equivalent proceedings or any other prosecution activities, (b) to defend all such applications against Third Party oppositions or other
challenges (other than any challenges in response to an enforcement against any Competitive Infringement pursuant to Section 7.2 that are not administered by any patent office or like Governmental Authority), (c) to secure the grant of any
patents arising from such patent application, (d) to maintain in force any issued patent (including through payment of any relevant maintenance fees), (e) obtain and maintain patent term extension or supplemental protection certificates or
their equivalents, and (f) to make all decisions with regard to any of the foregoing activities. 
 1.45 “Regulatory
Approval” means, with respect to a country or region in the Territory, approvals, licenses, registrations or authorizations from the relevant Regulatory Authority necessary in order to import, distribute, market or sell a pharmaceutical
product (including any Licensed Product) in such country or region, but not including any pricing or reimbursement approvals or decisions. 

1.46 “Regulatory Authority” means the FDA, the EMA, and any other analogous government regulatory authority or agency involved
in granting approvals (including any required pricing or reimbursement approvals) for the development, manufacture or commercialization of any pharmaceutical product (including any Licensed Product) in the Territory. 

1.47 “Regulatory Filing” means any documentation comprising or relating to or supporting any filing or application with any
Regulatory Authority with respect to any compound or product (including the Licensed Compound or any Licensed Product), or its use or potential use in humans, including any documents submitted to any Regulatory Authority and all supporting data,
including INDs and NDAs, and all correspondence with any Regulatory Authority with respect to such compound or product (including minutes of any meetings, telephone conferences or discussions with any Regulatory Authority). 

1.48 “Royalty Patent Rights” means the Aerpio Patent Rights and the Licensee Patent Rights. 

1.49 “Sublicensee” means any Affiliate of Licensee or any Third Party in each case that has been granted a sublicense (or an
option or right of negotiation or refusal for a sublicense) by Licensee under Section 5.1(a) and in accordance with Section 5.2. 

1.50 “Subsidiary/Parent Sale” means, with regard to [***] any direct or indirect parent Affiliate of Licensee, any
transaction, [***], that would constitute a Change of Control [***]. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 6 

 1.51 “Transaction Payments” means all consideration in any form,
including merger consideration, equity or other securities purchase price, exercise price, option purchase price, option fee, upfront, marketing, distribution, franchise, milestone, royalties or license payments, profit shares, fees, bonuses or
other payments, paid (directly or indirectly) to, or for the benefit of, Licensee, its Affiliates, or equity or other security holders (or former equity or other security holders) of Licensee or any of its Affiliates from any Sublicensees or other
Third Parties solely with respect to any (a) grant of license or other rights by Licensee or any of its Affiliates to the Licensed Compound or any Licensed Product, including any distribution rights or any sublicense under any of the Aerpio
Patent Rights or Aerpio Know-How (other than by any Program Transaction) or (b) Program Transaction, in each case provided that to the extent that the consideration from any such transaction includes
contingent payments related to future events or release of escrowed amounts, such payments and amounts shall be included as Transaction Payments only as and when such payments and amounts are received (directly or indirectly) by or on behalf of
Licensee or its Affiliates or such equity or other security holders (or former equity or other security holders). Not included in Transaction Payments shall be any consideration attributable to the sale or transfer of physical assets, leases or
inventory, and with respect to clause (a) (but not clause (b)) above, the following will not be treated as Transaction Payments: (i) payments to reimburse Licensee for research or development activities or for patent prosecution costs specific
to any Licensed Product, and (ii) payments made for debt or securities of Licensee up to fair market value (with any premium on debt or securities included as “Transaction Payments” hereunder). 

1.52 “Territory” means worldwide. 

1.53 “Third Party” means any person or entity other than Licensee or Aerpio or any of their respective Affiliates. 

1.54 “Valid Claim” means (a) a claim of an issued and unexpired patent, which claim has not been held invalid or
unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through
re-examination or disclaimer, opposition procedure, nullity suit or otherwise and (b) a claim of any patent application that has been pending for fewer than seven (7) years after the earliest
priority date of such patent application. 
 The following additional defined terms have the meanings set forth in the section indicated: 

 

			
	 Defined Term
	  	Section
	AAA	  	Section 11.8(b)
	Additional Third Party Licenses	  	Section 6.3(d)
	Aerpio	  	Introductory Paragraph
	Aerpio Core Patent Rights	  	Section 1.4
	Aerpio Indemnitees	  	Section 9.5(a)
	Affected Party	  	Section 10.4
	Agreement	  	Introductory Paragraph
	Alliance Manager	  	Section 2.2(f)
	Bankruptcy Event	  	Section 10.4
	Claim	  	Section 9.5(c)
	CREATE Act	  	Section 7.1(e)
	Disclosing Party	  	Section 8.1(a)
	Effective Date	  	Introductory Paragraph
	Hatch-Waxman Time Period	  	Section 7.2(b)
	Indemnitee	  	Section 9.5(c)
	Indemnitor	  	Section 9.5(c)
	Issuing Party	  	Section 8.2(c)

  
 7 

			
	Defined Term	  	Section
	JDC	  	Section 2.2(a)
	Licensee	  	Introductory Paragraph
	Licensee Indemnitees	  	Section 9.5(b)
	Losses	  	Section 9.5(a)
	Milestone Events	  	Section 6.2
	Milestone Payments	  	Section 6.2
	Party	  	Introductory Paragraph
	Receiving Party	  	Section 8.1(a)
	Release	  	Section 8.2(c)
	Reversion IP	  	Section 10.6(d)
	Reviewing Party	  	Section 8.2(c)
	Royalty Term	  	Section 6.3(b)
	SEC	  	Section 1.6
	Sublicense	  	Section 5.2(b)
	Term	  	Section 10.1
	20% Amount	  	Section 6.4(a)
	Working Group	  	Section 2.2(a)

 Section 2. Development. 

2.1 General. The JDC’s overall responsibility shall be to encourage and facilitate ongoing cooperation between the Parties with
respect to the development activities contemplated by this Agreement and to coordinate the development of the Licensed Products for the Indications covered by each Development Plan. 

2.2 Joint Development Committee. 

(a) Formation; Purposes. Within thirty (30) days after the Effective Date, Aerpio and Licensee will establish a
joint development committee (the “JDC”) composed of no more than three (3) representatives of each Party. The JDC will have responsibility for (i) reviewing and overseeing the overall progress of development and
manufacturing activities under this Agreement with respect to Licensed Products for use in the Territory and in the Field, including oversight of the various budgets and activities, (ii) overseeing the implementation of all development
operational aspects of the arrangements established by this Agreement, and (iii) forming various working group(s) (each, a “Working Group”) to oversee particular projects or activities from time to time and delegating to such
Working Group(s) such operational responsibilities as the JDC may determine necessary or desirable. In conducting its activities, including in the allocation of activities to the Parties under each Development Plan, the JDC will operate and make its
decisions consistent with the terms of this Agreement. 
 (b) Membership. The JDC will be composed of an equal number
of representatives appointed by each of Aerpio and Licensee. Each Party will have the right, but not be obligated, to appoint the same number of representatives to the various Working Groups as are appointed by the other Party; however, each Party
will have collectively one vote, as set forth in Section 2.2(e)(i), regardless of the number or representatives from each Party. The Parties may from time to time change the size of the JDC. Each Party may replace JDC and any Working Group
representatives at any time upon written notice to the other Party. The JDC and the various Working Groups will be co-chaired by one designated representative of each Party. The
co-chairpersons of each committee and Working Group will not have any greater authority than any other representative on the committee or Working Group. The
co-chairperson of Licensee will be responsible for: (a) calling meetings; (b) preparing and circulating an agenda in advance of each meeting, provided that the
co-chairperson will include any agenda items proposed by either Party on such agenda; (c) ensuring that all decision-making is carried out in 

  
 8 

 
accordance with the voting and dispute resolution mechanisms set forth in this Agreement; and (d) preparing and issuing minutes of each meeting within thirty (30) days thereafter. Each
Party may designate the same individual as a representative on more than one committee or Working Group, and such individual may be an employee or consultant of such Party or any of its Affiliates. Each Party will be responsible for all costs and
expenses incurred by it in participating in the JDC and any Working Groups. 
 (c) Meetings of the JDC and Working
Groups. The JDC will hold meetings at such times as the JDC will determine, but in no event will such meetings of the JDC be held less frequently than once every six (6) months during the Term for so long as the JDC exists. Each Working
Group will hold meetings at such times as the Working Group agrees, or as the JDC directs. Each of the JDC and the Working Groups may meet in person or by audio or video conference as the Parties may mutually agree. Other representatives of the
Parties, their Affiliates and Third Parties involved in the development, manufacture or commercialization of the Licensed Compound and Licensed Products may attend such meetings of the JDC or Working Groups as nonvoting observers. The JDC and
Working Groups may upon agreement meet on an ad hoc basis between regularly scheduled meetings in order to address and resolve time-sensitive issues within their purview that may arise from time to time. No action taken at a meeting of the JDC or
any Working Group will be effective unless a representative of each Party is present or participating. Neither Party will unreasonably withhold attendance of at least one representative of such Party at any meeting of a committee or Working Group
for which reasonable advance notice was provided. 
 (d) JDC Specific Responsibilities. The JDC will: 

(i) review and discuss the research and development activities for the Licensed Compound and Licensed Products; 

(ii) review and discuss the implementation of each Development Plan and the corresponding Development Budget; 

(iii) review and discuss each Development Plan, including the corresponding Development Budget set forth therein, on an annual basis,
including new Development Plans and corresponding Development Budgets, and review and discuss amendments and updates to each Development Plan and corresponding Development Budget; 

(iv) review and discuss non-clinical research or development of the Licensed Compound and Licensed
Products; 
 (v) review and discuss clinical development of the Licensed Compound and Licensed Product in all Indications subject of a
Development Plan, including clinical study design, clinical study endpoints, clinical methodology and monitoring requirements; and 
 (vi)
perform such other functions as are assigned to it in this Agreement or as are appropriate to further the purposes of this Agreement as agreed in writing by the Parties. 

(e) JDC Decision-Making. 

(i) Other than as set forth herein, in order to make any decision required of it hereunder with respect to any approval, the JDC must have
present (in person, by videoconference or telephonically) at least one member of each Party. The Parties will endeavor to make decisions of the JDC by consensus. 

(ii) The JDC will attempt in good faith to resolve any disputes or failure to agree by unanimous consent (with each Party having one vote). If
the JDC cannot resolve such dispute or failure to agree within thirty (30) days of the matter being referred to it, such matter will be resolved pursuant to Section 11.8(a) by referral directly to a senior executive of each Party
designated by such Party’s Executive Officer (but not Section 11.8(b)). If such matter is not resolved pursuant to the dispute resolution process 

  
 9 

 
set forth in Section 11.8(a), then Licensee will have the tie-breaking vote, provided that no decision by Licensee may be in conflict with any of the
terms of this Agreement (including by amending or increasing any obligations on Aerpio or any of its Affiliates or by granting any licenses or other rights to Licensee or any of its Affiliates that, in each case, are not expressly set forth in this
Agreement). 
 (iii) Notwithstanding anything herein to the contrary, with respect to any decision to be made by any of the JDC or the
various Working Groups, each Party will exercise its voting right (including Licensee’s tie-breaking vote of Section 2.2(e)(ii)) in good faith and in a manner consistent with its obligations under
this Agreement, including Sections 2.4(a) and 3.1(a). 
 (iv) Neither the JDC nor any Working Group will have the authority to
amend or modify this Agreement. 
 (f) Alliance Managers. Each Party will designate a single alliance manager for all
of the activities contemplated under this Agreement (“Alliance Manager”). Such Alliance Managers will be responsible for the day-to-day worldwide
coordination of the arrangements contemplated by this Agreement and will serve to facilitate communication between the Parties. Such Alliance Managers will have experience and knowledge appropriate for managers with such project management
responsibilities. Each Party may change its designated Alliance Manager from time to time upon notice to the other Party. 

(g) Term. The JDC, and any Alliance Manager relationship described in Section 2.2(f), will continue until the
initial Regulatory Approval of the initial Licensed Product in the United States or a Major European Country, unless otherwise agreed by the Parties in writing, provided that Aerpio may, at its sole discretion, elect to dissolve the JDC or the
Alliance Manager at any time. 
 (h) Notwithstanding anything to the contrary herein, Licensee may, in its sole discretion,
dissolve the JDC or any Working Groups or Alliance Manager in the event of a Change of Control of Aerpio. 
 2.3 Development Plan;
Amendments; Development Responsibilities. 
 (a) Development Plan. The global development of the Licensed
Products, including pre-clinical development activities, will be governed on an Indication-by-Indication basis by a Development
Plan, and Licensee agrees to conduct (and to cause its Affiliates and Sublicensees to conduct) all of Licensee’s development activities relating to the Licensed Products in accordance with each Development Plan at Licensee’s sole cost and
expense. The terms of and activities set forth in each Development Plan will at all times be designed to be in compliance with all applicable Law and to be conducted in accordance with professional and ethical standards customary in the
pharmaceutical industry. 
 (b) Development Budget. A Development Budget will be included in each Development Plan.

 (c) Updating and Amending Each Development Plan. 

(i) The JDC will review each Development Plan and develop updates as necessary. Upon the JDC’s preliminary approval, such updates will be
submitted to Licensee for its internal budgeting process with a target for final approval by the JDC. No amendments to updates to any Development Plan (including the corresponding Development Budget), nor any new Development Plan (with corresponding
Development Budget), will be effective without the approval of the JDC. 
 (ii) Exhibit B-2 sets for
the Development Budgets for the initial Development Plans set forth in Exhibit B-1, and those Development Budgets include a high-level forecast of anticipated budget amounts and associated timelines for the
applicable development. 

  
 10 

 2.4 Development Efforts; Manner of Performance; Reports. 

(a) Development Efforts. Licensee will use Commercially Reasonable Efforts to develop, and seek Regulatory Approval for,
Licensed Products containing the Licensed Compound for use in at least the United States, two Major European Countries, and Japan for at least one of the Initial Indications. All other development and commercialization efforts with respect to the
Licensed Compound and Licensed Products shall be at the discretion of Licensee. Without limiting the generality of the foregoing, Licensee will use Commercially Reasonable Efforts to perform, or cause others to perform, each Development Plan as set
forth therein (including in accordance with the applicable Development Budget and timelines set forth therein). Licensee will conduct, and will cause its Affiliates and Sublicensees to conduct (as applicable), all research and development activities
in good scientific manner and in compliance with applicable Law, including Laws regarding environmental, safety and industrial hygiene, and GLP, GCP, current standards for pharmacovigilance practice, and all applicable requirements relating to the
protection of human subjects. 
 (b) Responsibility; Cost and Expense. As between the Parties, Licensee will be solely
responsible, at its sole cost and expense, for all research and development activities under this Agreement (including the performance of each Development Plan), and all associated manufacturing. 

(c) Development Reports. In the event that Licensee has not received Regulatory Approval for a Licensed Product in
[***], Licensee will prepare and maintain, and will cause each of its Affiliates and Sublicensees to prepare and maintain (as applicable), reasonably complete and accurate records regarding the development activities on the Licensed Compound or
Licensed Products that have been performed. Each calendar year, Licensee will provide to Aerpio a written progress report that includes information of Licensee and its Affiliates and Sublicensees regarding accrual, site initiation, progress on
protocol writing, meeting requests and briefing documents, in the case of clinical or regulatory activities, and in other cases such information as is reasonably necessary to convey a reasonably comprehensive understanding of the status of the
applicable research or development activity. In addition to the foregoing, Licensee will immediately provide notice to Aerpio in the event that the development of the Licensed Compound or any of the Licensed Products, or any Indications in
development, is suspended or terminated, or if any significant adverse events have occurred, as defined by the applicable Regulatory Authority. 

(d) Aerpio Know-How Transfer and Technical Assistance. 

(i) Know-How Transfer. During the [***] period following the Effective Date, Aerpio will
endeavor to provide to Licensee all tangible embodiments of all Aerpio Know-How in its possession and Control, including one (1) electronic copy of all documents, data or other information in
Aerpio’s Control to the extent that such documents, data or other information describe or contain Aerpio Know-How (including any clinical studies on the Licensed Compound). 

(ii) Technical Assistance. During the six (6) month period following the Effective Date, Aerpio will reasonably cooperate with
Licensee to provide (i) up to two hundred fifty (250) hours of technical assistance without charge to Licensee (with travel and accommodation expenses to be borne by Licensee) and (ii) any additional hours of technical assistance as
Licensee may reasonably request, for which Licensee will pay Aerpio a rate of [***] dollars (also “USD”) ($[***]) for C-level executives, [***] U.S. dollars ($[***]) for VP-level employees and [***] U.S. dollars ($[***]) for other employees, in each case per hour of such technical assistance and reimburse Aerpio for all
out-of-pocket expenses incurred in providing such technical assistance under this clause (ii), in each case to facilitate the transfer of development efforts
related to the Licensed Compound and Licensed Products. Such cooperation will 
  
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 11 

 
include providing Licensee with reasonable access by teleconference or in-person at Aerpio’s facilities to Aerpio personnel involved in the
development of the Licensed Compound and Licensed Products to provide Licensee with a reasonable level of technical assistance and consultation in connection with the transfer of Aerpio Know-How. 

(iii) Aerpio agrees that, during the Term and subject to Section 8.4, any Aerpio Know-How
disclosed to or required to be disclosed to Licensee shall be treated as Licensee Confidential Information hereunder (in addition to being treated as Aerpio Confidential Information), but only to the extent any such Aerpio Know-How relates solely to the Licensed Compound and is not excepted from the confidentiality obligations pursuant to Section 8.1(b). Notwithstanding the foregoing or anything else contained herein, Licensee
may publish or otherwise disclose Aerpio Know-How to the extent reasonably related to any Licensed Compound or Licensed Products. 

2.5 Regulatory Filings and Regulatory Approvals. 

(a) Responsibility; Cost and Expense. As between the Parties, Licensee will solely be responsible, at its sole cost and
expense, for seeking and attempting to obtain all Regulatory Approvals for the Licensed Products for use in the Territory and in the Field, including in accordance with each Development Plan. 

(b) Ownership of Regulatory Approvals. As between the Parties, Licensee will own all Regulatory Filings and Regulatory
Approval for the Licensed Products for use in the Territory and in the Field filed by Licensee or any of its Affiliates or Sublicensees. 

(c) Regulatory Cooperation. Licensee will provide, and will cause its Affiliates and Sublicensees to provide (as
applicable), Aerpio with advance drafts of any material documents or other material correspondence pertaining to Regulatory Approvals, including any proposed labeling, that is planned to be submitted to any Regulatory Authority. Aerpio may provide
comments regarding such documents and other correspondence prior to their submission, which comments Licensee and its Affiliates and Sublicensees will consider in good faith. Licensee will provide, and will cause its Affiliates and Sublicensees to
provide (as applicable), Aerpio with copies of all material submissions it makes to, and all material correspondence it receives from, a Regulatory Authority pertaining to a Regulatory Approval. Notices, copies of submissions and correspondence, and
other materials to be given in advance as provided in this Section 2.5(c) will be provided at least [***] in advance unless circumstances necessitate a shorter time period, and in any event not less than a reasonable time in advance under the
circumstances. For clarity, during the Term, Aerpio shall have no right to, and shall not, make any regulatory filings related to the Licensed Compound or Licensed Products or otherwise interact with any Regulatory Authorities with respect to the
Licensed Compound or Licensed Product, unless compelled or involuntarily required by Law. 
 Section 3. Commercialization. 

3.1 Commercialization Efforts; Manner of Performance; Reports; Pricing; Markings. 

(a) Commercialization Efforts. Licensee will use Commercially Reasonable Efforts to commercialize Licensed Products for
use in the Territory and in the Field in those countries and for those Indications for which Regulatory Approval (and, if applicable, pricing or reimbursement approval or decision) has been obtained. Without limiting the generality of the foregoing,
Licensee will use Commercially Reasonable Efforts to execute and to perform, or cause to be performed, the Commercialization Plan. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 12 

 (b) Responsibility; Cost and Expense. As between the Parties,
Licensee will be solely responsible, at its sole cost and expense, for all commercialization activities under this Agreement (including under the Commercialization Plan), and all associated manufacturing. 

(c) Commercialization Reports. Licensee will prepare and maintain and will cause its Affiliates and Sublicensees to
prepare and maintain (as applicable), reasonably complete and accurate records regarding the commercialization activities for Licensed Products. Each calendar quarter, Licensee will provide to Aerpio a written progress report that describes
commercialization activities that Licensee and its Affiliates and Sublicensees has performed or caused to be performed since the last progress report submitted. 

(d) Pricing and Reimbursement. As between the Parties, Licensee will be responsible for and have the exclusive right to
seek and obtain pricing and reimbursement approvals for the Licensed Products for use in the Territory and in the Field. 

(e) Commercialization Markings. All promotional materials, packaging and product labeling for Licensed Products will
contain to the extent not prohibited by applicable Law, the corporate name of Aerpio (in a form and manner to be provided by Aerpio), and further will indicate that the Licensed Product was in-licensed from
Aerpio. 
 3.2 Commercialization Plan and Budget. 

(a) Commercialization Plan. Licensee will develop a Commercialization Plan that sets forth the commercialization
activities to be undertaken with respect to Licensed Products for use in the Territory and in the Field (which may set forth commercialization activities for use in the Territory and in the Field on a regional basis, rather than a country-by-country basis, defining the regions in a manner consistent with Licensee’s internal procedures). Licensee will use Commercially Reasonable Efforts to
commercialize the Licensed Compound and Licensed Products in accordance with the Commercialization Plan and this Agreement. The Commercialization Plan (including the Commercialization Budget) will be provided to Aerpio and will be updated at least
annually by Licensee. The terms of and activities set forth in the Commercialization Plan will at all times be designed to be in compliance with all applicable Law and to be conducted in accordance with professional and ethical standards customary
in the pharmaceutical industry. 
 (b) Commercialization Budget. The Commercialization Budget will be included in the
Commercialization Plan and will be a written budget setting forth the budgeted amounts for costs with respect to activities set forth in the Commercialization Plan during the then-current calendar year and [***], broken down by calendar quarter for the then current calendar year. The Commercialization Budget also will include a breakout of costs by functional area or category (and may set forth budgets
for commercialization activities in the Territory on a regional basis, rather than a country-by-country basis, defining the regions in a manner consistent with
Licensee’s internal procedures). 
 Section 4. Manufacturing. 

Licensee will be solely responsible, at its sole cost and expense, for manufacturing and supplying the worldwide requirements for the research, development and
commercialization of the Licensed Compound and Licensed Products for use in the Territory and in the Field. The manufacturing contracts of Aerpio for the Licensed Compound or Licensed Products listed on Exhibit G hereto will be assigned to Licensee
within [***] of the Effective Date. Notwithstanding the foregoing, upon request by Licensee within [***] of the Effective Date, Aerpio shall sell to Licensee at Aerpio’s cost of goods plus delivery costs some or substantially all quantities (as
requested by Licensee) of the Licensed Compound or Licensed Product in its possession. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 13 

 Section 5. Licenses and Other Rights. 

5.1 Exclusive License Grants. 

(a) Aerpio Patents and Aerpio Know-How. Subject to the terms and conditions of
this Agreement, Aerpio hereby grants to Licensee a non-transferable (except in accordance with Section 11.1), exclusive (even as to Aerpio), royalty- and milestone-bearing license, with the right to
sublicense in accordance with Section 5.2 only, under the Aerpio Patent Rights and Aerpio Know-How, to make, have made, use, sell, offer to sell, import, develop, and commercialize the Licensed Compound
and the Licensed Products, for use in the Territory and in the Field. 
 (b) INDs. Subject to the terms and conditions
of this Agreement, Aerpio hereby grants to Licensee a non-transferable (except in accordance with Section 11.1), exclusive (even as to Aerpio), royalty- and milestone-bearing right of reference, with the
right to grant further rights of reference only to those person or entities that have been granted a sublicense by Licensee under the license grant in Section 5.1(a) in compliance with Section 5.2, to the INDs listed on Exhibit D,
solely for the Licensed Compound and Licensed Products, for use in the Territory and in the Field. 
 (c) Aerpio In-License. Subject to the terms and conditions of this Agreement and the Aerpio In-License, Aerpio hereby grants to Licensee and its Affiliates a non-transferable (except in accordance with Section 11.1), royalty- and milestone-bearing (solely as set forth in Section 6 of this Agreement) sublicense, with no right to sublicense further, under the
Licensed Patents (as defined in the Aerpio In-License), of the non-exclusive rights under those Licensed Patents granted to Aerpio under the Aerpio In-License, up to but not more than the scope and term of the license granted by Aerpio to Licensee under Section 5.1(a) (and in any event not more than what was granted to Aerpio under the Aerpio In-License). At Licensee’s reasonable request, Aerpio will grant to Licensee’s Sublicensees a sublicense under the Aerpio In-License equivalent to the grant above,
subject to this Section 5.1(c) and the remainder of this Agreement and pursuant to a mutually agreeable written agreement, without any requirements for further consideration or additional obligations. Subject to the terms and conditions of this
Agreement, the foregoing sublicense by Aerpio to Licensee will be exclusive as to Aerpio but, for clarity, not the UC Regents per the Aerpio In-License, and save for the continuing right to grant sublicenses
in accordance with the immediately preceding sentence. Any sublicense under the Aerpio In-License is subject to the terms of this Agreement and the Aerpio In-License
(including Article 4 thereof), and further and without limitation, Section 4.3 thereof (and the provisions of the Aerpio In-License identified therein) are hereby incorporated by reference and made
applicable to Licensee as a sublicensee for the benefit of the UC Regents. It is understood and agreed that Licensee and no other sublicensee of Aerpio under the Aerpio In-License will be a third party
beneficiary of the Aerpio In-License. For clarity, any sub-license under Section 5.1(a) under the Aerpio In-License will be
subject to the terms and conditions of the Aerpio In-License and this Section 5.1(c). Aerpio represents and warrants that Licensee will not be obligated to make any payments to UC Regents under the Aerpio
In-License. Aerpio shall be liable for any and all payments that may become due to UC Regents under the Aerpio In-License with respect to Licensee’s activities
under this Agreement, including any activities related to the development or commercialization of Licensed Products. 
 (d)
Scope Clarification. The licenses and other rights granted in this Section 5.1 and the remainder of this Agreement will not grant or create (by implication, estoppel or otherwise) any license or right under any Aerpio Patent Rights,
Aerpio Know-How, INDs listed on Exhibit D, or under the Aerpio In-License, to research, develop, manufacture or commercialize, make, use, sell, offer to sell or
import any molecule that is not a Licensed Compound or any other molecule Covered by the Aerpio Patent Rights (including any other therapeutically active molecule in any Licensed Product). 

  
 14 

 5.2 Sublicenses. 

(a) Licensee may grant sublicenses (or any option or right of negotiation or refusal for a sublicense) of the license granted
under Section 5.1(a) and the rights granted under Section 5.1(b) only as follows: 
 (i) to any Affiliate of Licensee as a
Sublicensee hereunder, provided such sublicense (or any option or right of negotiation or refusal for a sublicense) only remains in effect for as long as such Sublicensee remains an Affiliate of Licensee; 

(ii) to non-Affiliated Third Parties that are clinical research organizations, contract manufacturers,
contract laboratory organizations, and other similar organizations that support the development and commercialization of the Licensed Compound and Licensed Products on a
fee-for-service basis as Sublicensees hereunder, provided that such sublicenses (or options or rights of negotiation or refusal for a sublicense) include obligations of
confidentiality and non-use of Aerpio Patent Rights, Aerpio Know-How and Confidential Information of Aerpio substantially in accordance with the terms of this Agreement;
and 
 (iii) to other non-Affiliated Third Parties as a Sublicensee hereunder, provided that only
one (1) such non-Affiliated Third Party may be a Sublicensee at any given time in any given geographic area in the Territory. 

(b) Each sublicense (or any option or right of negotiation or refusal for a sublicense) granted by a Licensee to a non-Affiliated Third Party pursuant to this Section 5.2 is required to (i) be in writing; and (ii) be subject and subordinate to, and consistent with, the terms and conditions of this Agreement.
Licensee will provide Aerpio with a copy of each agreement containing any such sublicense (or any option or right of negotiation or refusal for a sublicense) within thirty (30) days of execution. No sublicense (or any option or right of
negotiation or refusal for a sublicense) will diminish, reduce or eliminate any obligation of Licensee under this Agreement, and Licensee will remain responsible for its obligations under this Agreement and will be responsible for the performance of
the relevant Sublicensee as if such Sublicensee were “Licensee” hereunder. Each sublicense (or any option or right of negotiation or refusal for a sublicense) granted by Licensee to any rights licensed to it hereunder will, at the option
of Aerpio, either be (i) assigned to Aerpio or (ii) terminate immediately upon the termination of the license under Section 5.1(a) from Aerpio to Licensee. 

5.3 License Limitations. Except as expressly set forth in this Agreement, no licenses or other rights are granted or created hereunder
to use any patent right, Know-How or other intellectual property rights owned or in-licensed by Aerpio or any of its Affiliates or licensors. All licenses and other
rights are or will be granted only as expressly provided in this Agreement, and no other licenses or other rights is or will be created or granted hereunder by implication, estoppel or otherwise. 

5.4 Exclusivity. 

(a) During the Term, Aerpio will not (either alone or with any of its Affiliates), directly or indirectly, develop, manufacture
or commercialize, or collaborate with, enable or otherwise authorize, license, sublicense, or otherwise grant any right to any Third Party, to develop, manufacture or commercialize, any compound that primarily binds to HIF prolyl hydroxylase
resulting in HIF stabilization anywhere in the Territory. 
 (b) During the Term, Licensee will not (either alone or with any
of its Affiliates), directly or indirectly, [***], enable or otherwise authorize, license, sublicense, or otherwise grant any 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 15 

 
right to any Third Party, to [***] any compound (except for Licensed Compounds and any compound contained in Licensed Products) that [***]. 

Section 6. Payment. 
 6.1 Initial
License Fee. Licensee will pay to Aerpio within five (5) days after the Effective Date a one-time payment in cash of twenty million U.S. dollars ($20,000,000), which payment will be non-refundable and non-creditable and not subject to set-off. 

6.2 Milestone Payments. As set forth in the following table, Licensee will make the following payments in cash (the “Milestone
Payments”) to Aerpio upon achievement of each of the milestone events set forth in the tables below (the “Milestone Events”) by Licensee or its Affiliates or Sublicensees. Each Milestone Payment will be payable by Licensee
to Aerpio within [***] after the achievement of the corresponding Milestone Event with respect to the first Licensed Product in each of the first and second Initial Indications. Such payments will be
non-refundable and non-creditable and not subject to set-off. 

 

			
	“Clinical Development Milestones”
	 “Milestone
Event”
	  	“Milestone Payment”
	Initiation (i.e., first patient, first dosing) of first Phase 2 Clinical Trial for the first Licensed Product for the first Initial Indication to achieve such milestone	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	For clarity, each Clinical Development Milestone payment is due only once regardless of the number of Licensed Products developed by Licensee.

 If the first [***] for the first Licensed Product for the first [***] in the foregoing table is skipped [***] then the
[***]for the first Licensed Product for the [***] will be deemed to have been achieved upon the achievement of [***] for the first Licensed Product [***]. 
  

			
	“Commercial Milestones”
	 “Milestone
Event”
	  	“Milestone Payment”

  

			
	First Commercial Sale in the United States following achievement of Regulatory Approval by the FDA for	  	$[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 16 

			
	the first Licensed Product for the first Initial Indication to achieve such milestone	  	
	First Commercial Sale in the United States following achievement of Regulatory Approval by the FDA for the first Licensed Product for the second Initial Indication to achieve such milestone	  	$[***]
	First Commercial Sale in a Major European Country following achievement of Regulatory Approval by the EMA for the first Licensed Product for the first Initial Indication to achieve such milestone	  	$[***]
	First Commercial Sale in a Major European Country following achievement of Regulatory Approval by the EMA for the first Licensed Product for the second Initial Indication to achieve such milestone	  	$[***]
	First Commercial Sale in Japan following achievement of Regulatory Approval in Japan for the first Licensed Product for the first Initial Indication to achieve such milestone	  	$[***]
	First Commercial Sale in Japan following achievement of Regulatory Approval in Japan for the first Licensed Product for the second Initial Indication to achieve such milestone	  	$[***]
	For clarity, each Commercial Milestone payment is due only once regardless of the number of Licensed Products developed by Licensee.
	
	“Sales Milestones”
	 “Milestone
Event”
	  	“Milestone Payment”
	First achievement of USD $[***] of annual Net Sales of all Licensed Products in the Territory in a particular Calendar Year	  	$[***]
	First achievement of USD $[***] of annual Net Sales of all Licensed Products in the Territory in a particular Calendar Year	  	$[***]
	First achievement of USD $[***] of annual Net Sales of all Licensed Products in the Territory in a particular Calendar Year	  	$[***]
	First achievement of USD $[***] of annual Net Sales of all Licensed Products in the Territory in a particular Calendar Year	  	$[***]
	For clarity, each Sales Milestone payment is due only once regardless of the number of Licensed Products commercialized by Licensee or the number of times the Sales Milestone is met.

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 17 

 6.3 Royalties. 

(a) Royalties. Licensee will pay to Aerpio running royalties in cash at the graduated royalty rates specified in the
following table with respect to the aggregate annual worldwide Net Sales of all Licensed Products in a calendar year: 
  

			
	 Aggregate Annual Worldwide Net Sales of All Licensed Products in a
calendar year
	  	Royalty Rate
	Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory up to and including USD $[***]	  	[***]%
	Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory between USD $[***] and USD $[***]	  	[***]%
	Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory between USD $[***] and USD $[***]	  	[***]%
	Portion of cumulative Calendar Year Net Sales of Licensed Products in the Territory exceeding USD $[***]	  	[***]%

 The applicable royalty rate will be calculated as provided in this Section 6.3(a) by reference to the aggregate annual
worldwide Net Sales of all Licensed Products. By way of example, [***]. 
 (b) Royalty Term. The royalties due under
Section 6.3(a) will be payable on Net Sales from the First Commercial Sale of a particular Licensed Product until the later of, on a country-by-country basis,
(i) the date of expiration of the last-to-expire Valid Claim of any Aerpio Patent Right (including any applicable patent term extension) that Covers the
manufacture, use, sale, offer for sale or importation of such Licensed Product in such country, (ii) if such Licensed Product contains AKB-4924, the date of expiration of the last-to-expire Valid Claim of any Licensee Patent Right (including any
applicable patent term extension) that Covers the manufacture, use, sale, offer for sale or importation of such Licensed Product in such country, or (iii) fifteen (15) years from such First Commercial Sale of such Licensed Product in such
country (the “Royalty Term”). 
 (c) Only One Royalty. Only one royalty will be due with respect to
the sale of the same unit of Licensed Product. Only one royalty will be due hereunder on the sale of the same unit of Licensed Product even if more than one claim of the Royalty Patent Rights Covers such Licensed Product. 

(d) Anti-Stacking. In the event that Licensee reasonably determines that it is necessary for Licensee to obtain a
license to any patent rights from a Third Party to commercialize (including to make, have made, use, sell, offer for sale, have sold or import any Licensed Product for such commercialization) (“Additional Third Party Licenses”) and
Licensee obtains such an Additional Third Party License, then Licensee may deduct from the royalty payment that would otherwise have been due to Aerpio, an amount equal to [***] percent ([***]%) of the royalties actually paid to such Third Party
under such Additional Third Party Licenses by Licensee to commercialize (including to make, have made, use, sell, offer for sale, have sold or import for such commercialization, as applicable) such Licensed Product, provided that pursuant to this
Section 6.3(d) the royalties owed by Licensee to Aerpio for a particular Licensed Product shall not be reduced to less than [***] percent ([***]%) of the amount otherwise owed. 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 18 

 (e) Know-How Royalty. In
countries in the Territory where a Licensed Product is not Covered by a Valid Claim of a Royalty Patent Right (i.e., under clause (i) of Section 6.3(b)), Licensee shall pay royalties on Net Sales of such Licensed Products in such
countries with respect to the Royalty Term at royalty rates that shall be set at [***] percent ([***]%) of the applicable royalty rate determined according to Section 6.3(a), mutatis mutandis. 

(f) Generic Competition. In the event that, on a Licensed Product-by-Licensed Product and country-by-country basis, a Generic Product(s) is commercially available with respect to such
Licensed Product in such country and the combined market share for such Generic Product(s) is [***]. 
 (g) Payment
Floor. In no event will any credits, deductions or reductions permitted to be taken under this Agreement against any particular royalty payment owed to Aerpio under this Section 6.3 (including under Section 6.3(d) or 6.3(e) or 6.3(f))
act to reduce such payment by more than [***] percent ([***]%) (or by more than [***] percent ([***]%) if the reduction set forth in Section 6.3(f) is then in effect) than would otherwise be payable hereunder in absent of any such credits,
deductions or reductions. Further, save for the permitted reductions pursuant to Section 6.3(d), 6.3(e), and 6.3(f), all royalties payable hereunder shall be non-refundable and non-creditable and not subject to set-off. 
 6.4 Transaction
Payments. 
 (a) Within [***] before or after the signing of any transaction that will (or could) give rise to any
[***] payment in excess of [***] Dollars ($[***]) (a “Qualifying Transaction”), Licensee will notify Aerpio of such Qualifying Transaction and provide Aerpio under confidentiality with (i) documentation regarding the nature and
amount of any Transaction Payments, including any upfront payments, (ii) Licensee’s good faith calculation of the amount and projected payment dates of those Transaction Payments, (iii) a calculation of [***] of the Transaction
Payments (including the projected payment dates), with the only reductions allowed from such [***] as permitted by Sections 1.51 and 6.4(d), or for taxes pursuant to Section 6.5(e), in each case if applicable (such [***] of those
Transaction Payments, the “[***]”), (iv) the expected date of the signing of such transaction, or if the signing has already occurred, the expected closing of such transaction, and (v) notification of whether Licensee is
exercising its option pursuant to Section 6.4(b). 
 (b) For any Qualifying Transaction, Licensee shall have the option
in its sole discretion to pay Aerpio the greater of (1) [***] Dollars ($[***]) or (2) the [***] of any upfront Transaction Payment, within [***] days after closing the Qualifying Transaction (or such earlier or later date when such upfront
Transaction Payment is received (directly or indirectly) by or on behalf of Licensee, its Affiliates, or equity or other security holders (or former equity or other security holders) of Licensee or any of its Affiliates), and Aerpio will no longer
be paid any amounts under Sections 6.2 and 6.3 accruing after the notification is provided to Aerpio pursuant to Section 6.4(a), subject to such Qualifying Transaction closing and (i) Licensee providing to Aerpio all of the final
documentation regarding such transaction, (ii) Aerpio receiving all of the [***] for such Qualifying Transaction (but subject to and based upon the last sentence of this Section 6.4(b)), and (iii) if applicable, the Parties compliance
with Section 6.4(d). To the extent the actual upfront Transaction Payment for such transaction is less than [***] Dollars ($[***]), the portion of such [***] Dollars ($[***]) payment that is in excess of the [***] of such upfront Transaction
Payment shall be creditable against any future [***] payments arising from any future Transaction Payments received (directly or indirectly) by or on behalf of Licensee, its Affiliates, or equity or other security holders (or former equity or other
security holders) of Licensee or any of its Affiliates for such Qualifying Transaction. In the event that License exercises 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 19 

 
its option under this Section 6.4(b), Licensee is obligated to pay, and will pay, to Aerpio such [***] for such Qualifying Transaction, but only as and within [***] of any Transaction
Payments for such Qualifying Transaction actually being received (directly or indirectly) by or on behalf of Licensee or its Affiliates or such equity or other security holders (or former equity or other security holders). 

(c) For any Qualifying Transaction for which Licensee does not exercise its rights pursuant to Section 6.4(b), within
[***] following the notification pursuant to Section 6.4(a), Aerpio will have the option in its sole discretion to elect by written notice to Licensee to be paid the [***], and upon making such election, and provided that Aerpio is paid at
least [***] percent ([***]%) of the [***] of the upfront payment amount provided pursuant to clause 6.4(a)(i), then Aerpio’s election will be irrevocable and Aerpio will no longer be paid any amounts under Sections 6.2 and 6.3
accruing after the notification is provided to Aerpio pursuant to Section 6.4(a), subject to such Qualifying Transaction closing and (i) Licensee providing to Aerpio all of the final documentation regarding such transaction and
(ii) Aerpio receiving all of the [***] for such Qualifying Transaction (but subject to and based upon the last sentence of this Section 6.4(c)), and (iii) if applicable, the Parties compliance with Section 6.4(d). In the event
that Licensor exercises its option under this Section 6.4(c) to receive the applicable [***], Licensee is obligated to pay, and will pay, to Aerpio such [***] for such Qualifying Transaction, but only as and within [***] of any Transaction
Payments for such Qualifying Transaction actually being received (directly or indirectly) by or on behalf of Licensee or its Affiliates or such equity or other security holders (or former equity or other security holders). 

(d) If Licensee is reasonably of the view that any transaction subject to Section 6.4 includes consideration attributable
to any physical assets, leases or inventory, or pharmaceutical products or drug candidates in addition to consideration attributable to the Licensed Compound and Licensed Products, [***], the portion of the consideration reasonably attributable to
the Licensed Compound and Licensed Products that will be the amount of the Transaction Payment that is subject to such [***] payment to Aerpio. If Licensee elects to exercise its option in Section 6.4(b), [***] on the portion of the
consideration reasonably attributable to the Licensed Compound and Licensed Products that will be the amount of the Transaction Payment that is subject to such [***] payment to Aerpio [***]. If the parties cannot agree on the [***]. 

(e) Notwithstanding the foregoing in this Section 6.4, if the ultimate parent Affiliate of Licensee undergoes a Change of
Control (where the reference to “Party” in such “Change of Control” definition refers to such parent entity), Licensee may by written notice to Aerpio notify Aerpio that this Section 6.4 will not apply to such Change of
Control [***]. 
 (f) All such payments to Aerpio under this Section 6.4 will be [***] For clarity, Aerpio shall not be
entitled to receive any [***] payments for any transaction that is not a Qualifying Transaction. 
 6.5 Payment Terms. 

(a) Manner of Payment. All payments to be made by Licensee hereunder will be made in United States dollars by wire
transfer to such bank account as Aerpio may designate. 
 (b) Reports and Royalty Payments. Subsequent to the First
Commercial Sale anywhere in the Territory and for as long as royalties are due under Section 6.3(a), Licensee will furnish to Aerpio a written report, within [***] after the end of each calendar quarter, showing the amount of Net Sales of
Licensed Products and royalty due for such calendar quarter. Royalty payments for each calendar quarter will be due at the same time as such written report for the calendar quarter. The report will include, at a minimum, the following information
for the applicable calendar quarter, each listed by product and by country of sale: (i) Net Sales for such Licensed Products sold by Licensee, Affiliates 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 20 

 
and Sublicensees; (ii) the royalties and Milestone Payments owed to Aerpio, listed by category; and (iii) the computations for any applicable currency conversions pursuant to
Section 6.5(d). All such reports will be treated as Confidential Information of Licensee. 
 (c) Records and
Audits. Licensee will keep, and will cause each of its Affiliates and Sublicensees to keep (as applicable), adequate books and records of accounting for the purpose of calculating all amounts due to Aerpio hereunder. For [***] next following the
end of the calendar year to which each will pertain, such books and records of accounting (including those of Licensee’s Affiliates and Sublicensees, as applicable) will be made available for inspection at reasonable times and upon reasonable
notice by an independent certified accountant selected by Aerpio, and which is reasonably acceptable to Licensee, for the sole purpose of inspecting the amounts due to Aerpio under this Agreement. In no event will such inspections be conducted
hereunder more frequently than once every [***] or cover more than [***] prior to the date of request for inspection. Such accountant must have executed and delivered to Licensee and its Affiliates and Sublicensees, as applicable, a confidentiality
agreement as reasonably requested by Licensee, which will include provisions limiting such accountant’s disclosure to Aerpio to only whether the royalty reports are correct or incorrect and the amount of any discrepancy. The results of such
inspection, if any, will be binding on both Parties if not disputed within [***] following receipt by the Parties of the inspection report. Any such dispute over an inspection report shall be subject to the dispute resolution procedure of
Section 11.8, and no payment shall be required until the dispute is resolved. If it is determined that Licensee underpaid, Licensee shall pay to Aerpio such amount it was determined to have underpaid plus interest as provided in
Section 6.5(g) within [***] of such determination. If it is determined that Licensee overpaid, Aerpio shall pay to Licensee such amount it was determined to have been overpaid within [***] days following such determination. Any undisputed
underpayments will be paid by Licensee within [***] days of notification of the results of such inspection. Any undisputed overpayments will be fully creditable against amounts payable in subsequent payment periods. Aerpio will pay for such
inspections, except that in the event there is any upward adjustment in amounts payable for any calendar year shown by such inspection of more than the greater of (i) [***] Dollars ($[***]) and (ii) [***] percent ([***]%) of the amount paid,
Licensee will reimburse Aerpio for any reasonable out-of-pocket costs of such accountant. Any underpayments or overpayments under this Section 6.5(c) will be
subject to the currency exchange provisions set forth in Section 6.5(d) as applied to the calendar quarter during which the payment obligations giving rise to such underpayment or overpayment were incurred by Licensee. 

(d) Currency Exchange. With respect to Net Sales invoiced in United States dollars, the Net Sales and the amounts due to
Aerpio hereunder will be expressed in United States dollars. With respect to Net Sales invoiced in a currency other than United States dollars, the Net Sales will be expressed in the domestic currency of the entity making the sale, together with the
United States dollars equivalent, calculated using the official rate of exchange of such domestic currency as quoted in the Wall Street Journal, New York edition, for the last business day of the calendar quarter for which payment is made. 

(e) Taxes. Aerpio shall be liable for all income and other taxes (including interest) imposed upon any payments made by
Licensee to Aerpio under this Section 6 or otherwise pursuant to this Agreement. Licensee may withhold from payments due to Aerpio amounts for payment of any withholding tax that is required by Law to be paid to any taxing authority with
respect to such payments. Licensee will provide Aerpio all relevant documents and correspondence, and will also provide to Aerpio any other cooperation or assistance on a reasonable basis as may be necessary to enable Aerpio to claim exemption from
such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Licensee will give proper evidence from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking
deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Licensee making payments from a single source in the U.S., where possible. 

  
 21 

 (f) Blocked Payments. In the event that, by reason of applicable Law
in any country, it becomes impossible or illegal for Licensee to transfer, or have transferred on its behalf, payments owed Aerpio hereunder, Licensee will promptly notify Aerpio of the conditions preventing such transfer and such payments will be
deposited in local currency in the relevant country to the credit of Aerpio in a recognized banking institution designated by Aerpio or, if none is designated by Aerpio within a period of thirty (30) days, in a recognized banking institution
selected by Licensee, as the case may be, and identified in a written notice given to Aerpio. 
 (g) Interest Due.
Licensee will pay Aerpio interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate of [***] percent ([***]%) per month or the maximum applicable legal rate, if less, calculated on the total
number of days payment is delinquent. 
 6.6 Mutual Convenience. The royalty and other payment obligations set forth hereunder have
been agreed to by the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts to Aerpio. Licensee hereby stipulates to the fairness and reasonableness of
such royalty and other payments obligations and covenants not to allege or assert (and to require its Affiliates not to allege or assert) that any such royalty or other payments obligations are unenforceable or illegal in any way, and to include
such covenant in any sublicense agreement. 
 Section 7. Patent Prosecution, Infringement and Extensions. 

7.1 Prosecution and Maintenance. 

(a) By the Parties Jointly. Promptly after the Effective Date, Aerpio will provide Licensee with copies of the
prosecution files for all patents and patent applications listed on Exhibit A. The Parties will cooperate in the Prosecution of the Aerpio Core Patent Rights, and Licensee will have final decision making authority for those Prosecution
activities. Licensee will act as the lead party and the party of record with each applicable Governmental Authority, and Licensee will select counsel reasonably acceptable to Aerpio (such acceptance not to be unreasonably withheld) in the Territory
for those Prosecution activities (which counsel, for clarity, will represent Licensee but not the Parties jointly). Each Party will provide to the other Party copies of any papers relating to the Prosecution of Aerpio Core Patent Rights promptly
upon receipt, or reasonably in advance of their filing, for the other Party to review and comment thereon, and Licensee will consider any Aerpio’s comments in good faith. Licensee and its counsel will prepare the first draft of all papers for
submission. Each Party (and its counsel) will have the right to review, and all reasonable comments will be accepted on, those papers. Licensee will be solely responsible for all costs and expenses incurred in connection with those Prosecution
activities. Aerpio will be responsible for any costs and expenses incurred by or on behalf of Aerpio. In Prosecuting the Aerpio Core Patent Rights, the Parties will endeavor to the extent practicable to maximize the patent term and patent protection
for the Licensed Compound and Licensed Products. 
 (b) By Aerpio. In no event will any of the Aerpio Core Patent
Rights fail to be filed or be permitted to lapse or be abandoned in any country, or no new patent application be filed claiming priority to a patent application with the Aerpio Core Patent Rights before such patent application’s issuance, or
extended, without Aerpio first being given an opportunity to assume full responsibility for the continued Prosecution of such Aerpio Core Patent Rights, unless such failure to file, lapse, abandonment or filing is jointly agreed upon by the Parties.
In the event that the Parties acting jointly cannot agree on whether or not to file or continue the Prosecution of or extend a patent application or patent within the Aerpio Core Patent Rights in any country at least [***] prior to any filing
deadline or 
  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 22 

 
pending lapse or abandonment thereof, Aerpio will have the right, but not the obligation, to assume sole responsibility for the Prosecution of such patent rights, with counsel of Aerpio’s
own choice, by delivery by Aerpio of written notice to Licensee of its election to assume such sole responsibility. Upon Aerpio’s delivery of the foregoing written notice, any such patent applications and patents will no longer be considered
“Aerpio Patent Right” hereunder and will be excluded from the license granted to Licensee under Section 5.1. Aerpio will assume sole responsibility for all costs and expenses arising from the Prosecution activities of such patent
applications and patents. 
 (c) Patent Extensions; Orange Book Listings; Patent Certifications. 

(i) Patent Term Extension. If elections with respect to obtaining patent term extension or supplemental protection certificates or
their equivalents in any country with respect to any Licensed Product becomes available, upon Regulatory Approval or otherwise, the Parties will discuss in good faith which issued patent to extend, and Licensee will have final decision making
authority for which issued patent to extend, provided that the only patent rights owned or in-licensed by Aerpio or any of its Affiliates that may be extended by Licensee by operation of this Agreement are
those Aerpio Core Patent Rights that Cover the applicable Licensed Product. 
 (ii) Data Exclusivity and Orange Book Listings. With
respect to data exclusivity periods (such as those periods listed in the Orange Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83, and all equivalents in any
country), Licensee, in consultation with Aerpio, will seek and maintain all such data exclusivity periods that may be available for any of the Licensed Products. The Parties will discuss in good faith which Aerpio Patent Rights, if any, will be
listed in the Orange Book or any similar patent listing in any country with respect to the Licensed Products, and Licensee will have final decision making authority for which patents will be listed. 

(iii) Notification of Patent Certification. Each Party will notify and provide the other Party with copies of any allegations of
alleged patent invalidity, unenforceability or non-infringement of an Aerpio Patent Right pursuant to a Paragraph IV Patent Certification by a Third Party filing an Abbreviated New Drug Application, an
application under §505(b)(2) of the FD&C Act, or any other similar patent certification by a Third Party, and any foreign equivalent thereof. Such notification and copies will be provided within five (5) business days after a Party
receives such certification, and will be sent to the other Party’ address set forth in Section 11.7. 
 (d)
Cooperation. Each Party will reasonably cooperate with the other Party in the Prosecution of the Aerpio Core Patent Rights. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees and
consultants and agents of such Party and its Affiliates, and for Licensee, Sublicensees, to execute all documents, including declarations and assignments, as reasonable and appropriate so as to enable the Prosecution of any such Aerpio Core Patent
Rights in any country. 
 (e) CREATE Act. Notwithstanding anything to the contrary in this Agreement, each Party will
have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. § 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its rights under this Agreement, but only with the prior written consent
of the other Party. In the event that a Party intends to invoke the CREATE Act, once agreed to by the other Party as required by the preceding sentence, it will notify the other Party and the other Party will cooperate and coordinate its activities
with such Party with respect to any filings or other activities in support thereof. 
 7.2 Enforcement. 

(a) By Licensee. In the event that Aerpio or Licensee becomes aware of any actual or suspected Competitive Infringement
of any Aerpio Core Patent Right within the scope of the license grant in Section 5.1, such Party will notify the other Party promptly, and following such notification, the 

  
 23 

 
Parties will confer. Licensee will have the initial right, but will not be obligated, to bring an infringement action with respect to such Competitive Infringement at its own expense, in its own
name and under its own direction and control, or settle any such action or proceeding. Aerpio will reasonably assist Licensee in any action or proceeding being prosecuted if so requested, and will be named in or join such action or proceeding if
requested by Licensee, and if so requested by Licensee, Licensee will bear all of Aerpio’s related legal costs and expenses. If Aerpio otherwise elects to be represented by its own legal counsel, Aerpio will bear all of Aerpio’s related
legal costs and expenses. 
 (b) By Aerpio. If Licensee elects not to bring any action for a Competitive Infringement
described in Section 7.2(a) within [***] after the becoming aware of such suspected Competitive Infringement, (and in all events at least [***] before the end of the applicable Hatch-Waxman Time Period, as defined below), then Aerpio may bring
such action at its own expense, in its own name and under its own direction and control, subject to the following: Licensee will reasonably assist Aerpio in any action or proceeding being defended or prosecuted if so requested, and will join such
action or proceeding at its own expense if requested by Aerpio. Licensee will have the right to participate in any such action or proceeding with its own counsel at its own expense. For purposes of this Agreement, “Hatch-Waxman Time
Period” means the applicable period of time during which a patent holder or licensee has the right to file an infringement suit to maintain certain rights and privileges upon receipt of Paragraph IV Patent Certification by a Third Party
filing an Abbreviated New Drug Application or an application under § 505(b)(2) of the FD&C Act, or any other similar patent certification by a Third Party, or any foreign equivalent thereof. 

(c) Withdrawal. If either Party brings an action or proceeding under this Section 7.2 and subsequently ceases to
pursue or withdraws from such action or proceeding (other than by settlement), it will promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section 7.2. 

(d) Damages. In the event that either Party exercises the rights conferred in this Section 7.2 and recovers any
damages or other sums in such action or proceeding or in settlement thereof, such damages or other sums recovered will first be applied to all out-of-pocket costs and
expenses incurred by the Parties in connection therewith (including attorney’s fees), unless expressly not reimbursable hereunder. If such recovery is insufficient to cover all such costs and expenses of both Parties, the controlling
Party’s costs will be paid in full first before any of the other Party’s costs. If after such reimbursement any funds will remain from such damages or other sums recovered, such funds will be allocated as follows: (i) to the extent
such recovery reflects lost profits damages, Licensee will retain such lost profits recovery, less the amounts that would otherwise be payable to Aerpio by treating such lost profits recovery as “Net Sales” with respect to such Licensed
Product; (ii) to the extent such recovery reflects reasonable royalty damages or other payments and Licensee is the controlling Party, [***]; and (iii) to the extent such recovery reflects reasonable royalty damages or other recoveries and
Aerpio is the controlling Party, [***]. 
 (e) Settlement of Litigation. No settlement, consent judgment or other
final disposition of an action for infringement or validity or misappropriation may be entered into as to any Aerpio Core Patent Rights without the prior written consent of Licensee, which consent shall not be unreasonably withheld. 

7.3 Patent Marking. Licensee will mark, and will cause all of its Affiliates and Sublicensees to mark, Licensed Products with all Aerpio
Patent Rights in accordance with applicable Law, which marking obligation will continue for as long as required under applicable Law. 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 24 

 Section 8. Confidential Information and Publicity. 

8.1 Confidentiality. 

(a) Confidential Information. Except as expressly provided herein, each of the Parties agrees that, for itself and its
Affiliates, and during the Term and for a period of ten (10) years thereafter, a Party and its Affiliates (the “Receiving Party”) receiving Confidential Information of the other Party or its Affiliates
(the “Disclosing Party”) will (i) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (ii) not
use such Confidential Information for any purpose except those licensed or otherwise authorized or permitted by this Agreement. 

(b) Exceptions. The obligations in Section 8.1(a) will not apply with respect to any portion of the Confidential
Information that the Receiving Party can show by competent proof: 
 (i) is publicly disclosed by the Disclosing Party, either before or
after it is disclosed to the Receiving Party hereunder; 
 (ii) was known to the Receiving Party or any of its Affiliates, without any
obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; 
 (iii) is subsequently
disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; 

(iv) is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed
to the Receiving Party; or 
 (v) has been independently developed by employees or contractors of the Receiving Party or any of its
Affiliates without the aid, application or use of Confidential Information of the Disclosing Party. 
 (c) Authorized
Disclosures. The Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(i) subject to Section 8.2 (including the exceptions provided therein), by either Party in order to comply with applicable Law (including
any securities Laws or regulation or rules of a securities exchange) or with a legal or administrative proceeding; 
 (ii) by either Party,
in connection with prosecuting or defending litigation, making regulatory filings, and Prosecuting Aerpio Core Patent Rights in accordance with Section 7; 

(iii) by Licensee, to its Affiliates, potential and future Sublicensees, permitted acquirers or assignees under Section 11.1,
subcontractors, investment bankers, investors, lenders, and each of Licensee’s and its Affiliates’ respective directors, employees, contractors and agents; and 

(iv) by Aerpio to its Affiliates, permitted acquirers or assignees under Section 11.1, subcontractors, investment bankers, investors
(including royalty purchasers), lenders, and each of Aerpio’s and its Affiliates’ respective directors, employees, contractors and agents, 

provided that (A) with respect to Section 8.1(c)(i) or 8.1(c)(ii), where reasonably possible, the Receiving Party will notify the Disclosing Party
of the Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the
confidentiality of the information to be disclosed, and (B) with respect to Sections 8.1(c)(iii) and 8.1(c)(iv), each of those named people and entities must be bound prior to disclosure by confidentiality and non-use restrictions at least as restrictive as those contained in this Section 8 (other than investment bankers, investors and lenders, who must be bound prior

  
 25 

 
to disclosure by commercially reasonable obligations of confidentiality). Further, with respect to Section 8.1(c)(i), in the event either Party intends to make a disclosure pursuant thereto,
the other Party will have a reasonable time period to review and comment on the proposed disclosure or filing that relates to this Agreement (including the right to request redaction of material terms to the extent permitted by any applicable Law),
and the Party intending to make such disclosure will consider in good faith any reasonable comments thereon provided by the other Party. 

8.2 Terms of this Agreement; Publicity. 

(a) Terms of this Agreement. The Parties agree that the terms of this Agreement will be treated as Confidential
Information of both Parties, and thus may be disclosed only as permitted by this Section 8. 
 (b) Restrictions.
Except as otherwise contemplated by this Section 8, neither Party to this Agreement will originate any publicity, news release or other public announcement, written or oral, relating to this Agreement, the transactions contemplated hereby or
the terms hereof, or the existence of any arrangement between the Parties, without the prior written consent of the other Party, whether named in such publicity, news release or other public announcement or not, except as required by applicable Law.

 (c) Review. In the event either Party (the “Issuing Party”) desires to issue any publicity,
new release or other public announcement relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party will provide the other Party (the “Reviewing Party”) with a copy of the proposed
release, announcement or statement (the “Release”). The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a reasonable period of time within which the Reviewing Party
may provide any comments on such Release and if the Receiving Party fails to provide any comments during the response period called for by the Issuing Party, the Reviewing Party will be deemed to have consented to the issuance of such Release;
provided, however, that as it relates to the disclosure of the results of any clinical trial conducted by Licensee or any health or safety matter related to a Licensed Product, each Party acknowledges that announcements may need to be made on
extremely short notice, and although a Party will endeavor to provide the other Party adequate time for such a review, such Party will be free to make necessary public disclosures as promptly as it deems necessary and appropriate. If the Reviewing
Party provides any comments, the Parties will consult on such Release and work in good faith to prepare a mutually acceptable Release. If the Reviewing Party does not provide its consent, not to be unreasonably withheld, to the issuance of the
Release, the Issuing Party will not issue the Release except as required by Law (including to comply with any securities Laws or regulation or rules of a securities exchange) or as otherwise expressly set forth herein. Each Party acknowledges and
agrees that the other Party may submit this Agreement to the SEC and if a Party does submit this Agreement to the SEC, such Party agrees to consult with the other Party with respect to the preparation and submission of, a confidential treatment
request for this Agreement. Licensee acknowledges that Aerpio is a publicly traded company and, as such, is legally obligated to make timely disclosures of all material events relating to its business, and will be required to file this Agreement
with the SEC. If a Party is required by Law to make a disclosure of the terms of this Agreement in a filing with or other submission to the SEC, and it is understood and agreed that Aerpio will need to make such public filing with the SEC,
(i) such Party has provided copies of the disclosure to the other Party reasonably in advance to the extent practicable under the circumstances, (ii) such Party has promptly notified the other Party in writing of such requirement and any
respective timing constraints, and (iii) such Party has given the other Party a reasonable time under the circumstances from the date of notice by such Party of the required disclosure to comment upon, request confidential treatment or approve
such disclosure, then such Party will have the right to make such public disclosure at the time and in the manner reasonably determined by its counsel to be required by Law. Notwithstanding anything to the contrary herein, it is hereby understood
and agreed that if a Party seeking to make a disclosure to the SEC as set forth in this Section 8.2, and the other Party 

  
 26 

 
provides comments within the respective time periods or constraints specified herein or within the respective notice, the Party seeking to make such disclosure or its counsel, as the case may be,
will in good faith (A) consider incorporating such comments and (B) use reasonable efforts to incorporate such comments, limit disclosure or obtain confidential treatment to the extent reasonably requested by the other Party. 

(d) Press Release Regarding Execution of the Agreement. The Parties agree to issue the joint press release in Exhibit E
promptly following the Effective Date. 
 8.3 Relationship to the Confidentiality Agreement. This Agreement supersedes the
Confidentiality Agreement, provided that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of
this Agreement. 
 8.4 Publications. In order to protect its investment hereunder, Licensee may elect to maintain the confidentiality
of its Confidential Information, and may request that Aerpio maintain the confidentiality of the Aerpio Know-How that relates primarily to the Licensed Compound and Licensed Products, until applications for
patent rights have been filed with respect thereto. Accordingly, Aerpio shall not, and shall cause each of its Affiliates not to, make any publications or public disclosures regarding any Licensee Confidential Information, or Aerpio Know-How that relates primarily to the Licensed Compound or Licensed Products, without Licensee’s prior written consent, for, in the case of Aerpio Know-How, up to [***]
from Licensee first being notified of any such proposed publication or public disclosure, and in all events subject to any disclosure required by applicable Law. 

8.5 Clinical Trials. For clarity, Licensee shall have the right to publish the results or summaries of results of any clinical trials
conducted with respect to a Licensed Product in its sole discretion and without needing the consent of Aerpio. 
 8.6 Remedies. Each
Party shall be entitled to seek, in addition to any other right or remedy it may have, at law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or
threatened violation of this Section 8. 
 Section 9. Warranties; Limitations of Liability; Indemnification. 

9.1 Aerpio Representations and Warranties. Except as set forth on Schedule 9.1, Aerpio represents and warrants to Licensee that as of
the Effective Date: 
 (a) Aerpio is duly organized, validly existing and in good standing under the laws of the jurisdiction
in which it is organized, and it has full right and authority to enter into this Agreement and to grant the licenses and other rights to Licensee as herein described. 

(b) This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become a
valid and binding contract of Aerpio enforceable against Aerpio in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other Law affecting creditors’ rights generally from time to time in
effect, and to general principles of equity. 
 (c) The execution, delivery and performance of this Agreement does not
conflict with any other agreement, contract, instrument or understanding, oral or written, to which Aerpio is a party, or by which it is bound, nor will it violate any applicable Law. 

(d) All necessary consents, approvals and authorizations of all Governmental Authorities and other persons or entities required
to be obtained by Aerpio in connection with the 
  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 27 

 
execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

(e) There is no litigation, proceeding or investigation pending or threatened against or involving Aerpio in any court or
before any agency or regulatory body which could adversely affect Aerpio’s ability or right to enter into this Agreement. 

(f) Neither Aerpio, nor to the knowledge of Aerpio any of its employees, independent contractors or consultants or agents or
officers: (i) has ever been debarred or is subject to debarment or convicted of a crime for which a person could be debarred before a Regulatory Authority under applicable Laws, or (ii) has ever been under indictment for a crime for which
a person could be debarred under such Laws. 
 (g) Aerpio is the sole and exclusive owner of the entire right, title and
interest in and to the Aerpio Core Patent Rights and the Aerpio Know-How free and clear of all liens and other encumbrances, security interests, options and licenses. 

(h) Aerpio is the non-exclusive licensee of the Aerpio
In-License, and holds such license for such patent rights free and clear of all liens and other encumbrances, security interests, options and licenses. The Aerpio
In-License is in full force and effect and neither Aerpio nor, to the knowledge of Aerpio, UC Regents is in breach of the Aerpio In-License, and neither party to that
agreement has accused the other party of being in breach of Aerpio In-License. 
 (i)
The Aerpio Patent Rights and the Licensed Patents (as defined in the In-License Agreement) constitute all the patents and patent applications owned or Controlled by Aerpio that Cover (or could Cover upon
issuance of the patent application) the Licensed Compound. 
 (j) Aerpio has the right to grant the licenses and rights in
the Aerpio Patent Rights and grant the sublicense in the Licensed Patents (as defined in the In-License Agreement) it purports to grant to Licensee hereunder. 

(k) During the Term, Aerpio shall maintain the Aerpio In-License in good standing and
shall not take any action, or omit to take any action (including making necessary payments), which would result in a breach or early termination of the Aerpio In-License or any rights thereunder. Aerpio
covenants that it shall not amend, modify or supplement the terms of, or waive any rights under, the Aerpio In-License that would adversely impact Licensee’s rights hereunder without the prior written
consent of Licensee, such consent not to be unreasonably withheld, delayed or conditioned. Aerpio shall promptly notify Licensee upon receipt by Aerpio of any notice from UC Regents of any actual or alleged breach under the Aerpio In-License and Aerpio shall endeavor to cure any such breach within the allotted cure period and if it is unwilling or unable to do so, Aerpio shall timely notify Licensee and Licensee shall have the right to cure
such breach on Aerpio’s behalf. 
 (l) There are no adverse actions, suits or claims pending or, to the knowledge of
Aerpio, threatened against Aerpio in any court or by or before any governmental entity with respect to the Licensed Compound, the Aerpio Patent Rights, or the Aerpio Know-How and, to the knowledge of Aerpio,
there are no Third Party patents that would reasonably be expected to give rise to such actions, suits or claims. No Third Party has challenged the ownership, inventorship, scope, duration, validity, enforceability, priority or right to use the
Licensed Compound, the Aerpio Patent Rights, or the Aerpio Know-How (other than in connection with routine patent office prosecution), and, to the knowledge of Aerpio, there is no basis for any such challenge.

 (m) Except for the matter with UC Regents that resulted in the Aerpio In-License,
Aerpio has not initiated or been involved in any proceedings or claims in which it alleges that any Third Party is or was infringing or misappropriating the Aerpio Patent Rights or Aerpio Know-How, nor have

  
 28 

 
any proceedings been threatened by Aerpio, nor, to the knowledge of Aerpio, is there any basis for any such proceeding. 

(n) To the knowledge of Aerpio and notwithstanding 35 U.S.C. § 271(e) or any comparable Laws, the research, development,
manufacture, use or sale of the Licensed Compound does not infringe or misappropriate any patent rights, know-how rights, or other intellectual property rights of any Third Party. 

(o) Aerpio has provided to Licensee complete and accurate copies of each of the manufacturing agreements listed on Exhibit G.

 For purposes of this Agreement, “to the knowledge of Aerpio” (and like phrases) will mean the actual knowledge as of the Effective Date of the
individuals listed on Schedule 9.1(a), with no duty of inquiry other than inquiry of (i) Aerpio’s current officers, directors, employees, consultants and legal counsel and (ii) the individuals listed on Schedule 9.1(b). 

9.2 Licensee Representations and Warranties. Licensee represents and warrants to Aerpio that as of the Effective Date: 

(a) Licensee is duly organized, validly existing and in good standing under the laws of jurisdiction in which it is organized,
and it has full right and authority to enter into this Agreement and to accept the rights and licenses granted as herein described. 

(b) This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become a
valid and binding contract of Licensee enforceable against Licensee in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other Law affecting creditors’ rights generally from time to time in
effect, and to general principles of equity. 
 (c) The execution, delivery and performance of this Agreement does not
conflict with any other agreement, contract, instrument or understanding, oral or written, to which Licensee is a party, or by which it is bound, nor will it violate any applicable Law. 

(d) All necessary consents, approvals and authorizations of all Governmental Authorities and other persons or entities required
to be obtained by Licensee in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

9.3 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER AERPIO NOR LICENSEE MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND,
EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY AERPIO PATENT RIGHTS, AERPIO KNOW-HOW, PATENT RIGHTS LICENSED TO AERPIO UNDER THE AERPIO IN-LICENSE, INDs LISTED ON
EXHIBIT D, THE LICENSED COMPOUND, OR ANY LICENSED PRODUCTS, INCLUDING ANY WARRANTIES OF VALIDITY OR ENFORCEABILITY OF ANY PATENTS, TITLE, QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, PERFORMANCE OR NONINFRINGEMENT OF ANY THIRD PARTY
PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS. 
 9.4 Performance by Affiliates and Subcontractors. Each Party will have the right to
utilize the services of its Affiliates or Third Party subcontractors in connection with the performance of the activities for which it is responsible under the Development Plan or the Commercialization Plan; provided, however, that such Party will
remain responsible under this Agreement for the performance and compliance of such Affiliates and Third Party subcontractors and will, if required, grant sublicenses to them in compliance with the terms of this Agreement. The Party utilizing such
subcontractors also will ensure that such Affiliate or Third Party is subject to obligations protecting and limiting use and disclosure of Confidential Information, 

  
 29 

 
the Licensed Compound, Licensed Products, patent rights and Know-How at least to the same extent as set forth under this Agreement. 

9.5 Indemnification. 

(a) Licensee Indemnity. Licensee hereby agrees to indemnify, defend and hold Aerpio and its Affiliates, and their
respective employees, directors, agents and consultants, and their respective successors, heirs and assigns and representatives (“Aerpio Indemnitees”) harmless from and against all claims, liability, threatened claims, damages,
expenses (including reasonable attorneys’ fees), suits, proceedings, losses or judgments, whether for money or equitable relief, of any kind, including but not limited to death, personal injury, illness, product liability or property damage or
the failure to comply with applicable Law (collectively, “Losses”), arising from any Third Party claim due to (i) the research, development, commercialization (including promotion, advertising, offering for sale, sale or other
disposition), transfer, importation or exportation, manufacture, labeling, handling or storage, or use of, or exposure to, the Licensed Compound or any Licensed Products by or for Licensee or any of its Affiliates, Sublicensees, subcontractors,
agents and consultants; or (ii) Licensee’s (or its Affiliates’ and Sublicensees’) use or practice of Aerpio Patent Rights and Aerpio Know-How; or (iii) any material breach of any
obligation, representation or warranty of Licensee hereunder; or (iv) Licensee’s (or its Affiliates’ and Sublicensees’) gross negligence, recklessness or willful misconduct, except, in each case, to the extent that such Losses
arise from (A) infringement or misappropriation of patent or other intellectual property rights or know-how by any Aerpio Indemnitees, (B) the gross negligence, recklessness or willful misconduct of
any Aerpio Indemnitees, or (C) any material breach of any obligation, representation or warranty of Aerpio hereunder. 

(b) Aerpio Indemnity. Aerpio hereby agrees to indemnify, defend and hold Licensee and its Affiliates, and their
respective employees, directors, agents and consultants, and their respective successors, heirs and assigns and representatives (“Licensee Indemnitees”) harmless from and against all Losses arising from any Third Party claim due to
(i) the research, development, transfer, importation or exportation, manufacture, labeling, handling or storage, or use of, or exposure to, the Licensed Compound or any Licensed Products by or for Aerpio or any of its Affiliates, Sublicensees,
subcontractors, agents and consultants before, during, or after the Term; or (ii) Aerpio’s (or its Affiliates’ and Sublicensees’) use or practice of Aerpio Patent Rights and Aerpio
Know-How; or (iii) any material breach of any obligation, representation or warranty of Aerpio hereunder; or (iv) Aerpio’s (or its Affiliates’ and licensees’) gross negligence,
recklessness or willful misconduct, except, in each case, to the extent that such Losses arise from (A) infringement or misappropriation of patent or other intellectual property rights or know-how by any
Licensee Indemnitees, (B) the gross negligence, recklessness or willful misconduct of any Licensee Indemnitees, or (C) any material breach of any obligation, representation or warranty of Licensee hereunder. 

(c) Indemnification Procedure. A claim to which indemnification applies under Section 9.5(a) or Section 9.5(b)
will be referred to herein as a “Claim”. If any person or entity (each, an “Indemnitee”) intends to claim indemnification under this Section 9.5, the Indemnitee will notify the other Party (the
“Indemnitor”) in writing promptly upon becoming aware of any claim that may be a Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice will not relieve the Indemnitor of its
indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The Indemnitor will have the right to assume and control the defense of such Claim
at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided however that an Indemnitee will have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, if
representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other Party represented by such counsel in such proceedings. If the
Indemnitor does not assume the defense of such Claim as aforesaid, the Indemnitee may defend such Claim but will have no obligation to do so. The 

  
 30 

 
Indemnitee will not settle or compromise any Claim without the prior written consent of the Indemnitor, and the Indemnitor will not settle or compromise any Claim in any manner which would have
an adverse effect on the Indemnitee’s interests, without the prior written consent of the Indemnitee, which consent, in each case, will not be unreasonably withheld. The Indemnitee will reasonably cooperate with the Indemnitor at the
Indemnitor’s expense and will make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information will be subject to Section 8. 

9.6 Insurance. Each Party shall maintain in full force and effect during the Term and for a period of [***] after expiration or
termination of this Agreement, worker’s compensation and general liability insurance coverage all in such amounts and with such scope of coverages as are customary in the industry for companies of like size and activities, and, in addition,
Licensee shall maintain clinical trial liability and product liability insurance coverage in amounts no less that: (a) clinical trials coverage in a minimum amount of $[***] combined single limit per occurrence and in the aggregate and
(b) product liability coverage, in a minimum amount of $[***] combined single limit per occurrence and in the aggregate. The policies of insurance required by this Section 9.6 will be issued by an insurance carrier with an A.M. Best rating
of “A” or better. Licensee will name Aerpio as an additional insured under such policies. Upon written request, each Party shall provide evidence of such insurance to the other Party and ensure that the other Party will receive no less
than thirty (30) days’ notice of any cancelation, non-renewal or material change in such coverage. The coverage limits set forth herein will not create any limitation on Licensee’s liability to
Aerpio under this Agreement. 
 9.7 Licensee Planned Structure. As of the Effective Date, Licensee does not have any rights to any
pharmaceutical products or drug candidates other than the Licensed Compound and Licensed Products and is wholly owned by its ultimate parent Affiliate, Gossamer Bio, Inc. 

Section 10. Term, Termination and Survival. 

10.1 Term. This Agreement will become effective as of the Effective Date and, unless sooner terminated in accordance with the terms
hereof or by mutual written agreement of the Parties, will continue on a country-by-country and Licensed
Product-by-Licensed Product basis until the end of the period during which royalties are due hereunder on Net Sales of such Licensed Product in such country (the
“Term”). Upon the end of such period for such Licensed Product in such country, the license grant contained in Section 5.1(a) will become perpetual, royalty-free and fully paid up with respect to such Licensed Product in such
country. 
 10.2 Termination for Safety or Efficacy. Notwithstanding anything contained herein to the contrary, Licensee shall have
the right to terminate this Agreement at any time in its sole discretion in the event of potential safety or efficacy concerns affecting the Licensed Compound or Licensed Product. Any termination under this Section 10.2 shall be accomplished by
Licensee giving [***] advance written notice to Aerpio. 
 10.3 Termination for Material Default. Either Party will have the right to
terminate this Agreement upon delivery of written notice to the other Party in the event of any material default in the performance by such other Party of any of such other Party’s material obligations under this Agreement, provided that such
default has not been cured [***], or, in the event such default results in a failure to make any material payment when due hereunder, [***], after written notice thereof is given by the non-defaulting Party to
the defaulting Party specifying the nature of the alleged default. 
 10.4 Termination for Insolvency. To the extent permitted by Law,
upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors (a “Bankruptcy Event”) by either
Party, Aerpio, in the case of a Bankruptcy Event by Licensee, or Licensee, in the case of a Bankruptcy Event by Aerpio, 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 31 

 
may terminate this Agreement; provided, however, that, in the case of any involuntary bankruptcy proceeding, such right to terminate will only become effective if the subject Party consents to
the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. All rights and licenses granted under or pursuant to this agreement are and shall otherwise be deemed to be, for purposes of Section 365(n) of
the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code and Licensee as licensee under this
Agreement and Aerpio will retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code and foreign equivalents, including that upon commencement of a bankruptcy proceeding by or against such Party undergoing a
bankruptcy proceeding (the “Affected Party”) under the U.S. Bankruptcy Code or foreign equivalents, the non-Affected Party will be entitled to complete duplicates of or complete access
to, as such non-Affected Party deems appropriate, any Know-How and patent and other intellectual property rights and all embodiments hereof licensed or to be transferred
to such non-Affected Party hereunder by the Affected Party. Such Know-How, rights and embodiments will be promptly delivered to the
non-Affected Party (a) upon any such commencement of a bankruptcy proceeding and upon written request thereof by the non-Affected Party, unless the Affected Party
elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under the foregoing clause (a), upon the rejection of this Agreement by or on behalf of the Affected Party upon written request
therefore by the non-Affected Party. This Section 10.4 is without prejudice to any rights the non-Affected Party may have arising under the U.S. Bankruptcy Code,
foreign equivalents or other Law. 
 10.5 Termination by Aerpio for Patent Challenge. 

(a) Aerpio will have the right to terminate this Agreement upon written notice to Licensee in the event that Licensee or any of
its Affiliates or Sublicensees directly or indirectly asserts a Patent Challenge; provided that with respect to any such Patent Challenge by any non-Affiliate Sublicensee, Aerpio will not have the right to
terminate this Agreement under this Section 10.5 if Licensee (i) causes such Patent Challenge to be terminated or dismissed or (ii) terminates such Sublicensee’s sublicense to the Aerpio Patent Rights being challenged by the
Sublicensee, in each case within [***] of Aerpio’s notice to Licensee under this Section 10.5. In the event Licensee or any of its Affiliates intends to assert a Patent Challenge in any forum, not less than [***] prior to making any such
assertion, Licensee will provide to Aerpio a written disclosure of such assertion. Notwithstanding the foregoing, Aerpio’s termination right under this Section 10.5 will not apply to any Affiliate of Licensee that first becomes an
Affiliate of Licensee after the Effective Date, where such Affiliate of Licensee was undertaking activities in connection with a Patent Challenge prior to such Affiliate first becoming an Affiliate of Licensee; provided however that Licensee uses
commercially reasonable efforts to cause such Patent Challenge to terminate within [***] of such Affiliate first becoming an Affiliate of Licensee. 

(b) In lieu of exercising its rights to terminate under this Section 10.5, Aerpio may elect upon written notice to
increase all of the milestone payments due under Section 6.2 and royalties due under Section 6.3(a) by [***] percent ([***]%) which election will be effective retroactively to the date of the commencement of the Patent Challenge. 

(c) Licensee acknowledges and agrees that this Section 10.5 is reasonable, valid and necessary for the adequate protection
of Aerpio’s interest in and to the Aerpio Patent Rights, and that Aerpio would not have granted to Licensee the licenses under those Aerpio Patent Rights, without this Section 10.5. Aerpio will have the right, at any time in its sole
discretion, to strike this Section 10.5 (or any portion thereof) from this Agreement, and Aerpio will have no liability whatsoever as a result of the presence or absence of this Section 10.5 (or any struck portion thereof). 

 
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 32 

 10.6 Effect of Termination. 

(a) If this Agreement terminates for any reason (other than expiration), except as may otherwise be agreed in writing by the
Parties, Licensee will be responsible at its own expense for an orderly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices, of any then on-going clinical studies
hereunder for which it has responsibility. Licensee will consider in good faith any reasonable request from Aerpio that Licensee continue, at Aerpio’s cost and expense, any ongoing clinical studies at the time of termination, except if safety
issues would put patients at risk. Aerpio reserves the right to continue any ongoing clinical studies for any Licensed Products at its own expense at such time as Licensee is no longer responsible therefor. 

(b) If this Agreement terminates for any reason (other than expiration), Licensee and its Affiliates and Sublicensees will have
[***] thereafter in which to dispose of any inventory of Licensed Compound or Licensed Product, subject to the payment to Aerpio of any royalties or other amounts due hereunder thereon. 

(c) If this Agreement terminates for any reason (other than expiration), all licenses and other rights granted by Aerpio to
Licensee hereunder will automatically terminate (including any sublicenses to Licensee or any Sublicensees under the Aerpio In-License), and Licensee and its Affiliates and Sublicensees will have no further
rights to practice or reference any Aerpio Patent Rights, Aerpio Know-How or INDs listed on Exhibit D (except as expressly permitted by Sections 10.6(a) and 10.6(b)). Each Party will promptly return
to the other Party (or as directed by such other Party destroy and certify to such other Party in writing as to such destruction) all of such other Party’s Confidential Information that are in such Party’s (or its Affiliates’ or in
the case of Licensee’s Sublicensees’) possession or control, save that such Party will have the right to retain (i) one (1) copy of intangible Confidential Information of such other Party for legal purposes, and (ii) any of the
foregoing that such Party retains any license or other right hereunder. Licensee and its Affiliates and Sublicensees will not continue to develop, manufacture or commercialize the Licensed Compound or any Licensed Products. 

(d) If this Agreement is terminated by Licensee pursuant to Section 10.2 or by Aerpio pursuant to Sections 10.3 or 10.4 or
10.5 (but solely with respect to a Patent Challenge of Aerpio Core Patent Rights), [***] Licensee will provide to Aerpio, at [***] cost and expense, one (1) copy of the foregoing (including all other documents necessary to [***] (including all
completed and ongoing clinical studies)) and all documents contained in or referenced in any such items [***]. 
 (e) If this
Agreement is terminated by Licensee pursuant to Section 10.2 or by Aerpio pursuant to Sections 10.3 or 10.4 or 10.5 (but solely with respect to a Patent Challenge of Aerpio Core Patent Rights), [***]. 

(f) If this Agreement terminates for any reason (other than expiration), [***]. 

(g) As compensation for the rights and licenses of Aerpio set forth in Sections 10.6(d) and 10.6(e), if before
termination of this Agreement by Licensee pursuant to Section 10.2 or by Aerpio pursuant to Sections 10.3 or 10.4 or 10.5 (but solely with respect to a Patent Challenge of Aerpio Core Patent Rights) [***]. 

10.7 Survival. In addition to the termination consequences set forth in Section 10.6, the following provisions will survive
expiration or termination of this Agreement for any reason: Section 1, Section 5.3, Section 6 (but only with respect to payments accrued before any such expiration or termination), Section 8, Sections 9.3, 9.4, 9.5 and 9.6,
Section 10 and Section 11. Expiration or termination of this Agreement for any reason will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor
preclude either Party from 
  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 33 

 
pursuing all rights and remedies it may have hereunder or at law or in equity, with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any
obligation. All other rights and obligations will terminate upon termination or expiration of this Agreement. 
 Section 11. General Provisions.

 11.1 Assignment. 

(a) This Agreement may not be assigned by either Party, nor may either Party delegate its obligations or otherwise transfer
licenses or other rights created by this Agreement, except as expressly permitted hereunder or otherwise without the prior written consent of the other Party, which consent will not be unreasonably withheld; provided that without consent
(i) Licensee may assign this Agreement in full to (x) an Affiliate of Licensee, provided that Licensee will remain fully liable for the performance of its obligations under this Agreement by such Affiliate, and further that such assignee
Affiliate will assign this Agreement in full back to Licensee at such time as such assignee Affiliate is no longer an Affiliate of Licensee, or (y) its successor in connection with a Change of Control of Licensee, and (ii) Aerpio may
assign this Agreement in full to (m) an Affiliate of Aerpio, provided that Aerpio will remain fully liable for the performance of its obligations under this Agreement by such Affiliate, and further that such assignee Affiliate will assign this
Agreement in full back to Aerpio at such time as such assignee Affiliate is no longer an Affiliate of Aerpio, or (n) its successor in connection with a Change of Control of Aerpio. Each Party will provide prompt written notice to the other
Party of any such permitted assignment. 
 (b) Notwithstanding anything to the contrary in this Agreement, Aerpio may sell,
transfer, lend or assign its rights to any Third Party(ies) to receive payments under Section 6, and Aerpio may disclose Confidential Information of Licensee to one or more Third Parties in connection with any such assignment to enable the
Third Party(ies) to evaluate and monitor any such purchase or loan; provided that Licensee shall only be obligated to send payments due hereunder to not more than two entities. 

(c) Any permitted assignee will assume all assigned obligations of its assignor under this Agreement. The terms and conditions
of this Agreement will inure to the benefit of, and be binding upon, the legal representatives, successors and permitted assigns of the Parties. 

11.2 Limited Right to Set-Off. Without limiting Licensee’s rights under law or in equity,
Licensee may exercise a right of set-off against any and all amounts paid by Licensee pursuant to Section 9.1(k) to cure a breach of the Aerpio In-License by
Aerpio. 
 11.3 Change of Control of Aerpio. Notwithstanding anything to the contrary herein: (a) no patent rights, Know-How or other intellectual property rights not Controlled by Aerpio or any of its Affiliates before a Change of Control of Aerpio will be deemed Controlled for purposes of this Agreement after such Change of
Control, provided that any patent right that claims priority, directly or indirectly, to any other patent right first Controlled by Aerpio or any of its Affiliates before such Change of Control will be deemed Controlled by Aerpio thereafter no
matter when such patent right is filed or issued, and (b) only those assets (including those items described in clause (a) above) of Aerpio and its Affiliates (before a Change of Control) that are in existence at the time of Change of
Control will be subject to Section 5.4. 
 11.4 Severability. If any one or more of the provisions contained in this Agreement is
held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s)
adversely affects the rights of the Parties. The Parties will in such an instance use their reasonable best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as
practical, implement the purposes of this Agreement. 

  
 34 

 11.5 Cumulative Remedies. All rights and remedies of the Parties hereunder will be
cumulative and in addition to all other rights and remedies provided hereunder or available by agreement, at Law or otherwise. 
 11.6
Amendment; Waiver. This Agreement may not be modified, amended or rescinded, in whole or part, except by a written instrument signed by the Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other
will be enforceable if undertaken in a writing signed by the Party to be charged with the undertaking or waiver. No delay or omission by either Party hereto in exercising any right or power occurring upon any noncompliance or default by the other
Party with respect to any of the terms of this Agreement will impair any such right or power or be construed to be a waiver thereof. A waiver by either of the Parties of any of the covenants, conditions or agreements to be performed by the other
will not be construed to be a waiver of any succeeding breach thereof or of any other covenant, condition or agreement herein contained. 

11.7 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by
facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed
as follows: 
  

			
	If to Licensee, to:	  	GB004, Inc.
		  	3013 Science Park Road
		  	Suite 200
		  	San Diego, CA 92121
		  	Attention: General Counsel
		
	With a required copy to:	  	Latham & Watkins LLP
		  	12670 High Bluff Drive
		  	San Diego, CA 92130
		  	Attn: Steven T. Chinowsky, Esq.
		  	Facsimile: (858) 523-5450
		  	Email: steven.chinowsky@lw.com
		
	If to Aerpio, to:	  	Aerpio Pharmaceuticals, Inc.
		  	9987 Carver Road, Suite 420
		  	Cincinnati, OH 45242
		  	Attention: CEO
		
	With a required copy to:	  	Goodwin Procter LLP
		  	100 Northern Avenue
		  	Boston, MA 02210
		  	Attention: Kingsley L. Taft, Esq.

 or to such address as each Party may hereafter designate by notice to the other Party. A notice will be deemed to have been
given on the date it is received by all required recipients for the noticed Party. 
 11.8 Dispute Resolution. 

(a) In the event of any dispute between the Parties under this Agreement, the Parties will first attempt in good faith to
resolve such dispute by negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within [***] days, either Party may, by written notice to the other, have such dispute referred to a senior
executive of each Party designated by such Party’s Executive Officer, which senior executives will meet in person if requested 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 35 

 
by either such senior executive and attempt in good faith to resolve such dispute by negotiation and consultation for a [***] day period following receipt of such written notice. If such senior
executives do not resolve such dispute within such [***] day period, either Party may refer the matter to the Parties’ Executive Officers for attempted resolution, whereupon the Parties’ Executive Officers will meet in person, if requested
by either such Executive Officer and attempt in good faith to resolve such dispute by negotiation and consultation for a thirty (30) day period following such referral. 

(b) Subject to Section 2.2(e)(ii), if the Executive Officers do not resolve such dispute within such [***] day period,
either Party may at any time thereafter submit such dispute to be finally settled by arbitration administered in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) in effect at the time
of submission. The arbitration will be heard and determined by three (3) arbitrators. Licensee and Aerpio will each appoint one (1) arbitrator and the third arbitrator will be selected by the two (2) Party-appointed arbitrators, or,
failing agreement within [***] days following the date of receipt by the respondent of the claim, by the AAA. Such arbitration will take place in New York, NY. The award shall be made within [***] months of the filing of the notice of arbitration,
and the arbitrator(s) shall agree to comply with this schedule before accepting appointment. However, this time limit may be extended by agreement of the Parties or by the arbitrator(s) if necessary. The arbitration award so given will be a final
and binding determination of the dispute, and will be fully enforceable in any court of competent jurisdiction. Costs of arbitration are to be divided by the Parties in the following manner: Licensee will pay for the arbitrator it chooses, Aerpio
will pay for the arbitrator it chooses, and the costs of the third arbitrator will be divided equally between the Parties. Except in a proceeding to enforce the results of the arbitration or as otherwise required by Law, neither Party nor any
arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties. Notwithstanding this Section 11.8(b), any dispute between the Parties under this Agreement regarding the
scope, validity, enforceability of infringement of any patent rights will subject to Section 11.8(a) and thereafter not this Section 11.8(b) but rather any court or other forum. 

(c) Notwithstanding the dispute resolution procedures set forth in this Section 11.8, in the event of an actual or
threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific performance or other injunctive relief) in any court or other forum, without first submitting to any dispute resolution procedures
hereunder. 
 (d) Notwithstanding the provisions of this Section 11.8, disputes relating to intellectual property
rights, including disputes relating to the ownership, inventorship, enforceability, validity or scope of patent or other intellectual property rights, or other disputes for which a Party wishes to seek injunctive or other equitable relief, but not
any disputes under Section 6.4, shall not be subject to the terms of this Section 11.8 and may be submitted for resolution to a court of competent jurisdiction, and without the necessity of posting a bond for such disputes seeking
injunctive or other equitable relief (each, an “Excluded Claim”). The Parties agree that any dispute concerning an Excluded Claim that cannot be resolved by the Parties will be subject to the exclusive jurisdiction of the U.S.
federal or New York state courts within the New York counties of New York, and the Parties hereby submit to, and waive any objection to, personal jurisdiction and venue in such courts for such purpose, and both Parties waive any right they may have
under applicable law or otherwise to a right to a trial by jury for such purpose. 
 11.9 Governing Law. This Agreement will be
governed by and construed in accordance with the laws of the State of New York, without regard to its conflicts of law provisions; provided that any dispute relating to the scope, validity, enforceability or infringement of any patent rights will be
governed by, and construed and enforced in accordance with, the substantive laws of the jurisdiction from which such patent rights arose. 

  
 36 

 11.10 Relationship of the Parties. Each Party is an independent contractor under this
Agreement. Nothing contained herein is intended or is to be construed so as to constitute Aerpio and Licensee as partners, agents or joint venturers. Neither Party will have any express or implied right or authority to assume or create any
obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder (except for Licensee
Indemnitees other than Licensee and Aerpio Indemnitees other than Aerpio for purposes of Sections 9.5(a) or 9.5(b), as applicable). 

11.11 Entire Agreement. This Agreement (along with the Exhibits) contains the entire understanding of the Parties with respect to the
subject matter hereof and supersedes and replaces any and all previous arrangements and understandings, including the Confidentiality Agreement, whether oral or written, between the Parties with respect to the subject matter hereof. 

11.12 Headings. The captions to the several Sections hereof are not a part of this Agreement, but are merely guides or labels to assist
in locating and reading the several Sections hereof. 
 11.13 Waiver of Rule of Construction. Each Party has had the opportunity to
consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. 

11.14 Interpretation. Whenever any provision of this Agreement uses the term “including” (or “includes”), such
term will be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent words refer to this
Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. The term “or” means “and/or” hereunder. All definitions set forth herein will be deemed applicable whether the
words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any Sections include Sections and
subsections that are part of the related Section (e.g., a section numbered “Section 5.2” would be part of “Section 5”, and references to “Section 5.2” would also refer to material contained in the
subsection described as “Section 5.2(a)”). 
 11.15 Counterparts; Facsimiles or PDF. This Agreement may be executed in
one (1) or more counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. Facsimile or PDF execution and delivery of this Agreement by either Party will constitute a legal,
valid and binding execution and delivery of this Agreement by such Party. 
 [Remainder of this Page Intentionally Left Blank] 

 

  
 37 

 IN WITNESS WHEREOF, the Parties have caused this License Agreement to be executed by their
respective duly authorized representatives as of the Effective Date. 
  

			
	AERPIO PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Stephen Hoffman

		 	(Signature)
	Name:	 	Stephen Hoffman
	Title:	 	Chief Executive Officer
	
	GB004, INC.
		
	By:	 	 /s/ Christian Waage

		 	(Signature)
	Name:	 	 Christian Waage

	Title:	 	 Treasurer & Secretary

 EXHIBIT A 

AERPIO PATENT RIGHTS 
  

							
	 Country
	  	Application Number	 	Filing Date	 	Patent Number
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

							
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

  
  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 EXHIBIT B-1 

INITIAL DEVELOPMENT PLANS 
  

[***] 

 EXHIBIT B-2 

INITIAL DEVELOPMENT BUDGETS 
 [***] 

 EXHIBIT C 

LICENSED COMPOUND 
 AKB-4924 

 EXHIBIT D 

LICENSED COMPOUND INDs 
 Canada

 [***] 
 United States 

[***] 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 EXHIBIT E 

PRESS RELEASE 

 

 
 Aerpio Announces Exclusive License Agreement with Gossamer Bio for
AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease 

CINCINNATI & SAN DIEGO — (BUSINESS WIRE) — Jun. 25, 2018 — Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced an
exclusive global license agreement with a wholly owned subsidiary of Gossamer Bio, Inc., GB004, Inc. (“Gossamer”), for the development and commercialization of Aerpio’s HIF-1 alpha stabilizer, AKB-4924, along with other related compounds. The arrangement combines Aerpio’s deep understanding of HIF biology with Gossamer’s experience in inflammation, immunology and inflammatory bowel disease (IBD)
drug development. 
 AKB-4924 (to be known as GB004) is an investigational hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer in development for IBD. Unlike other HIF stabilizers in clinical development, which stabilize
HIF-2 and stimulate erythropoiesis, GB004 preferentially stabilizes HIF-1 alpha, and has profound anti-inflammatory and mucosal wound healing effects in animal models of
IBD. Based on pre-clinical study results, GB004 has demonstrated several potential advantages over existing therapies for the treatment of IBD, including a possible superior efficacy and safety profile and
once-daily oral route of administration. To date, Aerpio has conducted a Phase 1, single ascending dose study which found GB004 to be safe and well-tolerated. In May 2018, Aerpio initiated a 24-subject, Phase
1, multiple ascending dose study to further assess the pharmacokinetics, safety and tolerability of GB004 in healthy volunteers. 
 Under the terms of the
license agreement, Gossamer will pay Aerpio $20 million up front, potential development, regulatory, and sales milestones of up to $400 million, and royalties on worldwide net sales, which range from a high single digit to mid-teen percentage of net sales. Gossamer will be responsible for the remaining development, regulatory, and commercialization expenses for GB004. 

“Gossamer is the ideal partner to maximize the potential of GB004 in IBD,” said Stephen Hoffman, MD, PhD, Chief Executive Officer
of Aerpio. “The Gossamer team has a demonstrated track record of successful therapeutic development in IBD, specifically the 

 
development of Ozanimod in multiple sclerosis and IBD, as evidenced by the sale of Receptos to Celgene in 2015 for $7.2 billion. Our partnership allows us to focus our resources on our
ophthalmology and diabetes programs currently in development at Aerpio.” 
 Faheem Hasnain, Gossamer Bio’s Chairman and Chief Executive Officer,
stated “We are pleased to have found GB004 after thoroughly assessing a substantial number of opportunities. This program represents an important addition to the Gossamer portfolio of drug candidates aiming to address unmet medical needs.”

 Sheila Gujrathi, MD, Gossamer Bio’s President and Chief Operating Officer, said “The HIF-1 alpha
stabilization mechanisms represent truly novel biology with multiple putative benefits and a potential paradigm-changing approach to treating IBD patients.” 

About Aerpio Pharmaceuticals 
 Aerpio Pharmaceuticals,
Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound,
AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for diabetic retinopathy. For more information please visit www.aerpio.com. 

About Gossamer Bio 
 Gossamer Bio, Inc. is a
biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics in the autoimmune, allergy/inflammation, immuno-oncology and fibrosis disease areas. Gossamer’s goal is to create a business that
allows value creation and capture at the individual asset level, long-term sustainability, and continuity, while ultimately helping to improve the lives of patients. 

About AKB-4924 (GB004) 

GB004, a selective stabilizer HIF-1 alpha, is being developed for the treatment of inflammatory bowel disease. HIF-1 alpha is involved in mucosal wound healing and the reduction of inflammation in the gastrointestinal tract. Aerpio has completed a single ascending dose clinical trial of GB004 in healthy volunteers and has
initiated a multiple ascending dose study in healthy volunteers. 
 Forward Looking Statements 

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things, the timeline of, and other developmental plans for, GB004 for inflammatory bowel disease or otherwise, and the therapeutic potential of the Company’s product candidates, including
GB004, and the Company’s partnership with Gossamer Bio. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such 

 
factors include, among others, that the Company’s partnership with Gossamer Bio may not yield the intended benefits, the availability of funding needed to continue to develop GB004 or other
product development plans, the inherent uncertainties associated with the FDA and drug development process, competition in the industry in which the Company operates and overall market conditions. These forward-looking statements are made as of the
date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Investors should consult all the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the Company files with the SEC available at www.sec.gov. 

View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005370/en/ 

Source: Aerpio Pharmaceuticals, Inc. 
 Investor:

 Aerpio Pharmaceuticals, Inc. 
 Michael Rogers

 Chief Financial Officer 
 mrogers@aerpio.com 

Gossamer Bio, Inc.: 
 Bryan Giraudo 

Chief Financial Officer 
 bgiraudo@gossamerbio.com 

Media: 
 Gossamer Bio, Inc. 

PR@GossamerBio.com 
 Burns McClellan, on behalf of
Aerpio Pharmaceuticals, Inc. 
 Media 
 Justin
Jackson 
 jjackson@burnsmc.com 
 Investors 

Ami Bavishi 
 abhavishi@burnsmc.com 

 EXHIBIT F 

AERPIO IN-LICENSE 

 Subject to FRE 408 

 

 NON-EXCLUSIVE LICENSE AGREEMENT 

 

			
	Parties to the Agreement:	  	Aerpio Therapeutics, Inc.
		
		  	The Regents of the University of Colorado, a body corporate
		
	University Case Number:	  	CU2065H

 TABLE OF CONTENTS 

Article 1 – Definitions 

Article 2 – Grant and Reservation of Rights 

Article 3 – Economic Consideration 

Article 4 – Sublicensing 

Article 5 – Confidential Information 

Article 6 – Export 
 Article
7 – Patent Prosecution and Enforcement 
 Article 8 – Warranties, Indemnifications, and Insurance 

Article 9 – Duration, Conditions, Termination, and Conversion 

Article 10 – General 
  

 
 Appendix A
– Technology Specific Terms and Conditions 

  

					
	Non-Exclusive License Agreement	  	Page 1 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 This NON-EXCLUSIVE LICENSE AGREEMENT between
The Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado Denver, having an office at 12635 E. Montview Blvd., Suite 270, Aurora, CO 80045 (the “University”) and Aerpio
Therapeutics, a corporation having its principal office at 9987 Carver Rd., Suite 420, Cincinnati, OH 45242 (“Licensee” has the meaning assigned to it in Article 1) is effective November 1, 2016, (the “Effective
Date”). 
 BACKGROUND 
  

	 	1.	 The University is the owner of the Licensed Patents (“Licensed Patents” has the meaning
assigned to it in Article 1) related to University Case Number CU2065H. 

  

	 	2.	 This Agreement is executed as part of a settlement agreement executed between the parties on the same date
herewith in settlement of certain litigation instituted by Licensee in the Southern District of Ohio on August 23, 2016 (the “Settlement Agreement”), which is attached hereto. 

Accordingly, the parties agree as follows: 

GENERAL TERMS AND CONDITIONS 

Article 1 Definitions 

1.1    Definitions. The terms defined in the Preamble have their assigned meanings and the following terms, whether
used in the singular or plural, have the meanings assigned to them. 
  

	 	(a)	 “Affiliate” means any entity that controls, is controlled by, or is under common control with
Licensee. Control means the 

  

	 	(i)	 direct or indirect ownership of at least 50% of voting securities; 

 

	 	(ii)	 power to govern the financial and operating policies of the entity; or 

 

	 	(iii)	 power to appoint the management of the entity. 

 

	 	(b)	 “Agreement” means this Non-Exclusive License
Agreement, as amended from time to time. 

  

	 	(c)	 “Confidential Information” means the terms of the Agreement, but not the existence of the
Agreement. Confidential Information does not include the following: 

  

	 	(i)	 Information which at the time of disclosure had been previously published or was otherwise publicly available
through no fault of Recipient. 

  

					
	Non-Exclusive License Agreement	  	Page 2 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

	 	(ii)	 Information which becomes public knowledge after disclosure unless such knowledge results from a breach of this
Agreement. 

  

	 	(iii)	 Information which was already in Recipient’s possession prior to the time of disclosure as evidenced by
written records kept in the ordinary course of business or by proof of actual use. 

  

	 	(iv)	 Information that is independently developed without use of the confidential information. 

 

	 	(v)	 Information which is required to be disclosed by law, court order, or government regulation.

  

	 	(d)	 “Field of Use” has the meaning assigned to it in Appendix A. 

 

	 	(e)	 “Licensee” means the entity listed in the Preamble and any of its Affiliates.

  

	 	(f)	 “Licensed Patents” means the United States patents and patent applications listed in
Appendix A, together with any and all divisionals and continuations of those applications and the patents issued therefrom, including any reissues, reexaminations, or extensions of such patents, and claims of any continuations-in-part applications and resulting patents that are directed to inventions specifically described and enabled in the patents and patent applications listed in
Appendix A. 

  

	 	(g)	 “Licensed Product” means any product, service, or process, the making, use, offer for sale,
sale, importation or rendering of which would infringe one or more Valid Claims in the country in which it is made, used, sold, offered for sale, imported, or rendered; or any product which is manufactured, or any service which is rendered, using a
process which would infringe one or more Valid Claims in the country in which it is made, used, sold offered for sale, imported, or rendered. 

  

	 	(h)	 “Notice Date” means the date the party to whom notice is sent receives the notice at the
address indicated in Article 10.2. Notice Date does not mean actual notice. 

  

					
	Non-Exclusive License Agreement	  	Page 3 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

	 	(i)	 “Recipient” means a party who receives information from the other party to this Agreement.

  

	 	(j)	 “Senior Executives” means a person with authority to contractually bind the party.

  

	 	(k)	 “Settlement Agreement” has the meaning assigned to it in the Background.

  

	 	(l)	 “Sublicense” means a grant of rights by Licensee to a third party to make, have made, use,
have used, sell, have sold, import, have imported, exported, or have exported Licensed Product. 

  

	 	(m)	 “Sublicensee” means the third party granted a Sublicense from the Licensee.

  

	 	(n)	 “Term” has the meaning assigned to it in Article 9.1. 

 

	 	(o)	 “Territory” has the meaning assigned to it in Appendix A. 

 

	 	(p)	 “University Indemnitees” includes the University, its regents, employees, students, officers,
agents, affiliates, representatives, and inventors. 

  

	 	(q)	 “Valid Claim” means a pending or issued and unexpired claim of a Licensed Patent so long as
the claim has not been irrevocably abandoned or declared to be invalid through no fault of the Licensee in a non-appealable decision of a court or other government agency of competent jurisdiction.

 1.2    Other Definitional Provisions. 

 

	 	(a)	 All references to statutes and related regulations include 

 

	 	(i)	 any past and future amendments of those statutes and related regulations; and 

 

	 	(ii)	 any successor statues and related regulations. 

 

	 	(b)	 The words “including,” “includes,” and “include” are deemed to be followed by the
words “without limitation.” 

 1.3    All references to currency in this Agreement such as
“Dollars” or “$” refer to the lawful currency of the United States of America. 

  

					
	Non-Exclusive License Agreement	  	Page 4 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 Article 2 Grant and Reservation of Rights 

2.1    License. Subject to the terms and conditions of this Agreement and the Settlement Agreement, the University
grants to the Licensee a non-exclusive license to the Licensed Patents to make, have made, use, import, offer to sell, sell, and practice the Licensed Products in the Field(s) of Use and the Territory. 

2.2    Limitation on Rights. This Agreement confers no license or rights by implication, estoppel, or otherwise
under any patent applications or patents of the University other than the Licensed Patents, regardless of whether such patents are dominant or subordinate to the Licensed Patents. 

2.3    Reservation of Rights. The University retains all rights under the Licensed Patents, subject to the license
granted to Licensee under Article 2.1. Without limiting the foregoing sentence, the University expressly reserves the right to grant further non-exclusive licenses under the Licensed Patents to any third
parties to make, have made, use, import, offer to sell, sell, and practice Licensed Products in any fields of use and in all applicable territories. Further, the University retains the right to market the Licensed Patents to potential non-exclusive
licensees. 
 Article 3 Economic Consideration 

3.1    As consideration for the license and rights granted under this Agreement and the Settlement Agreement, Licensee
agrees to pay to the University the economic consideration specified in Appendix A. 
 Article 4 Sublicensing 

4.1    Sublicenses Permitted. Licensee may sublicense the rights granted in Article 2. 

4.2    Responsibility for Sublicensees. Licensee retains all responsibility for the performance of all Sublicensees
under a Sublicense as if the performance was carried out by the Licensee itself. 
 4.3    Required Provisions.
Licensee shall include the following provision for the benefit of the University in all Sublicenses: Article 7 Warranties, Indemnification, and Insurance. 

4.4     Termination of License or Sublicense. 

 

	 	(a)	 Licensee shall cause the Sublicense to be subject to the termination of this Agreement. 

 

	 	(b)	 Licensee shall require the automatic termination of the Sublicense in the event the Sublicensee institutes a
legal action challenging the validity of any Licensed Patent. 

  

					
	Non-Exclusive License Agreement	  	Page 5 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 4.5    Copy of Sublicense. Licensee shall submit to the
University a copy of each fully executed Sublicense agreement and any amendments to Sublicenses granted by the Licensee under this Agreement. The Sublicense agreements and amendments must be postmarked within 30 days of their execution. 

Article 5 Confidential Information 

5.1    Responsibilities. The parties shall vigilantly protect all Confidential Information from disclosure
to third parties. The parties shall not make disclosures of the Confidential Information without the written permission of the other party. For clarity, either party may disclose the existence of this Agreement, but neither party may disclose the
Confidential Information without the written permission of the other party, except as may be required to be disclosed by law, court order, or government regulation, provided that a party may only disclose those terms of this Agreement it is legally
required to disclose. Licensee may disclose Confidential Information, other than the Financial Conditions set forth in Paragraph 2 of Appendix A, to business partners or potential business partners to document the freedom to operate for any Licensed
Product, or to respond to any party that accuses Licensee of not having freedom to operate for any Licensed Product, provided that the business partner, potential business partner, or party receiving the Confidential Information is bound by an
agreement to maintain the confidentiality of the Confidential Information. Licensee may request in writing consent from the University to disclose, under obligations of confidentiality, the Financial Conditions set forth in Paragraph 2 of Appendix A
to certain business partners or potential business partners. The University hereby agrees to consider such requests in a timely manner and not unreasonably withhold consent. 

5.2    Ownership. All written documents containing Confidential Information and other material in tangible
form received by the Recipient under this Agreement remains the property of the disclosing party. Upon request of the disclosing party, the Recipient shall return such documents to the disclosing party or provide evidence of their destruction. 

5.3    CORA. Licensee acknowledges that the University is subject to the Colorado Open Records Act, C.R.S.
§§ 24-72-201, et seq. (CORA). All plans and reports marked “Confidential” shall be treated by the University as confidential to the extent permitted
under § 24-72-204. Certain categories of information, including trade secrets and information implicating legal privileges, are not required to be released in
response to requests for information under CORA. 

  

					
	Non-Exclusive License Agreement	  	Page 6 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 Article 6 Export 

6.1    Export Prohibition. Licensee shall not export or re-export Licensed
Patents, Licensed Products, know-how, confidential information or technical information to any country, individual, or entity except when such export or re-export is authorized in full compliance with the laws
and regulations of the United States, as applicable. 
 6.2    Applicable Law. Applicable laws and regulations
may include but are not limited to the Export Administration Regulations, the International Traffic in Arms Regulations, and the economic sanctions regulations administered by the U.S. Department of the Treasury. 

Article 7 Patent Prosecution and Enforcement 

7.1    University retains sole responsibility for the maintenance of the Licensed Patent in its sole discretion, but has
no obligation to maintain the Licensed Patent. 
 7.2    University retains sole responsibility to bring or prosecute
actions or suits against third parties for infringement in its sole discretion, but has no obligation to bring or prosecute any such suits or actions. 

Article 8 Warranties, Indemnifications, and Insurance 

8.1    The University warrants that, as of the effective date of this Agreement, the University has no knowledge of: 

 

	 	(a)	 any challenge or dispute regarding the University’s ability to grant the rights provided in Article 2 of
this Agreement; and 

  

	 	(b)	 any agreement with the Brigham and Women’s Hospital, Inc., or any Affiliate thereof that prevents the
University from granting the rights provided in Article 2 of this Agreement. 

 8.2    Disclaimer
of Warranties. 
  

	 	(a)	 THE UNIVERSITY MAKES NO OTHER REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
AND ASSUMES NO RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION BY LICENSEE OR ITS SUBLICENSEES, VENDEES OR OTHER TRANSFEREES OF LICENSED PRODUCTS OR ANY OTHER PRODUCTS OR PROCESSES INCORPORATING OR MADE BY USE OF THE
LICENSED PATENTS. 

  

					
	Non-Exclusive License Agreement	  	Page 7 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

	 	(b)	 THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE
USE OR SALE OF LICENSED PRODUCTS OR ANY OTHER PRODUCTS OR PROCESSES INCORPORATING OR MADE BY USE OF THE LICENSED PATENTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, SERVICE MARK, OR OTHER RIGHTS. 

 

	 	(c)	 Nothing in this Agreement may be construed as 

 

	 	(i)	 a warranty or representation by the University as to the validity or scope of any of the rights included in the
Licensed Patents; 

  

	 	(ii)	 a warranty or representation that the Licensed Patents or anything made, used, sold or otherwise disposed of
under this Agreement will or will not infringe patents, copyrights or other rights; 

  

	 	(iii)	 an obligation to furnish any know-how or services not expressly agreed
to in this Agreement, or 

  

	 	(iv)	 an obligation by the University to bring or prosecute actions or suits against third parties for infringement,
or to provide any services other than those specified in this Agreement. 

8.3    Indemnification. Licensee shall indemnify, defend, and hold University Indemnitees harmless from and against
all liability, demands, damages, losses, and expenses (including attorney fees), for death, personal injury, illness, property damage, noncompliance with applicable laws and any other claim, proceeding, demand, expense and liability of any kind
whatsoever in connection with or arising out of any of the following: 
  

	 	(a)	 The use by or on behalf of Licensee, its Sublicensees, directors, officers, employees, or third parties of any
Licensed Patents; 

  

	 	(b)	 The design, manufacture, production, distribution, advertisement, consumption, sale, lease, sublicense or use
of any Licensed Products or materials by Licensee, or other products or processes developed in connection with or arising out of the Licensed Patents; or 

  

	 	(c)	 Any right or obligation of Licensee under this Agreement. 

8.4    Insurance. Licensee shall, at its sole cost and expense, procure and maintain reasonable commercial general
liability insurance, including product liability coverage and coverage for Licensee’s indemnification obligation under this 

  

					
	Non-Exclusive License Agreement	  	Page 8 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 
Agreement, in commercially reasonable and appropriate amounts for the Licensed Product being used, sold, distributed, imported or rendered. Licensee shall provide proof of such insurance coverage
as of the Effective Date, and at any time after the Effective Date upon receipt of University’s written request to provide proof of such coverage. 

Article 9 Duration, Conditions, Termination, and Conversion 

9.1    Term. This Agreement is effective as of the Effective Date and expires on the expiration date of the last to
expire patents within the Licensed Patents unless terminated pursuant to Article 9.2 or 9.3. 
 9.2    Termination of
Agreement by Licensee. Licensee may terminate this Agreement at any time on 60 days prior written notice to the University, if Licensee does all of the following: 
  

	 	(a)	 Pays all amounts due as well as all non-cancelable costs to the
University through the termination date. 

  

	 	(b)	 Returns any Confidential Information provided to Licensee by the University in connection with this Agreement.

  

	 	(c)	 Licensee understands that if Licensee terminates the Agreement, University may seek to initiate legal
proceedings to enforce the Licensed Patents against Licensee should University conclude it has basis to do so. 

9.3    Termination by University. The University may terminate this Agreement if Licensee does and fails to cure,
within 30 days of notice, any of the following: 
  

	 	(a)	 Breaches any material provision of this Agreement. 

 

	 	(b)	 Violates any laws or regulations of applicable governmental entities that have a material adverse effect on the

  

	 	(i)	 University; or, 

  

	 	(ii)	 Licensee’s ability to perform its obligations under this Agreement. 

 

	 	(c)	 Institutes a legal action challenging the validity of any Licensed Patent. 

 

	 	(d)	 Institutes a legal action under that certain Material Transfer Agreement executed between the parties dated
July 9, 2012, as amended on July 9, 2013, that certain Material Transfer Agreement 

  

					
	Non-Exclusive License Agreement	  	Page 9 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

	 	
executed between the University and Akebia Therapeutics, Inc., dated May 26, 2009, that certain Institution Research Agreement executed between the parties dated August 2, 2012, that certain
Consulting Agreement executed between the parties and University Physicians, Inc., effective January 1, 2016, that certain Bilateral Confidentiality and Non-Disclosure Agreement entered between the parties
dated May 5, 2016, or otherwise breaches the terms of the Settlement Agreement. 

  

	 	(e)	 Fails to maintain insurance as provided for in Article 8. 

Article 10 General 
 10.1
Assignment by Licensee. Licensee may assign this Agreement as part of a sale, regardless of whether such a sale occurs through an asset sale, stock sale, merger or other combination, or any other transfer of (i) Licensee’s entire
business; or (ii) that part of Licensee’s business that exercises all rights granted under this Agreement, provided that Licensee shall provide the University with written notice of the assignment, including the new assignee’s contact
information, within 10 days of the assignment. Any other attempt to assign this Agreement by Licensee is null and void. 
 10.2 General
Notice. 
  

	 	(a)	 Notice under this Agreement is sufficient if given by registered mail, postage prepaid, and addressed to the
party to receive such notice at the addresses given below, or such other address as may hereafter be designated by notice in writing. Notice is effective at the time of mailing. 

The University shall mail all general notices to Licensee to the following address: 

Joseph Gardner, Ph.D. 
 Aerpio
Therapeutics, Inc. 
 9987 Carver Road 

Suite 420 
 Cincinnati, OH 45242

  

	 	cc:	 Vern Norviel 

Wilson Sonsini Goodrich & Rosati, PC 

650 Page Mill Road 
 Palo Alto, CA
94304-1050 

  

					
	Non-Exclusive License Agreement	  	Page 10 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 Licensee shall mail all general notices to the University to the following address: 

License Administrator, CU Case #CU2065H. 

CU Innovations 
 University of
Colorado Denver 
 12635 E. Montview Blvd., Suite 270 

Aurora, CO 80045 
  

	 	(b)	 Either party may change its address with written notice to the other party. 

10.3    Invalidation Notice. Licensee shall provide written notice to the University at least 90 days prior to
bringing an action seeking to invalidate any Licensed Patent or a declaration of non-infringement. Licensee shall include in such written notice an identification of all prior art it believes invalidates any
claim of the patent. 
 10.4    Use of Names and Marks: Licensee shall not identify the University in any
promotional advertising, press releases, sales literature or other promotional materials to be disseminated to the public or any portion thereof without the University’s prior written consent in each case, except that the Licensee may state
that it has a non-exclusive license for the Licensed Patents from the University. The University may state that it has a license for the Licensed Patents with Licensee. Licensee further shall not use the name
of the University or any University faculty member, inventor, employee or student or any trademark, service mark, trade name, copyright or symbol of the University, without the prior written consent of the University, entity or person whose name is
sought to be used. 
 10.5    Marking: Licensee shall cause Licensed Products sold under this Agreement to be
marked with the notice of the patent numbers or patent pending, as may be appropriate. 
 10.6    University Rules
and Regulations. Licensee acknowledges that University employees who are engaged by Licensee, whether as consultants, employees, or otherwise, or who possess a material financial interest in Licensee, are subject to the University’s rule
regarding outside activities and financial interests as set forth in the University’s intellectual property policy and related policies regarding conflicts of interest and outside consulting, as may be amended from time to time. Any term or
condition of an agreement between Licensee and a University employee that seeks to vary or override such employee’s obligations to the University may not be enforced against such personnel or the University without the express written consent
of the Principal Technology Transfer Officer as well as University Physicians, Inc., as applicable. 

10.7    Compliance with the Law. Licensee shall comply with all commercially material local, state, federal, and
international laws and regulations relating to its obligations under this Agreement regarding the development, manufacture, use, and sale of Licensed Products. 

  

					
	Non-Exclusive License Agreement	  	Page 11 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 10.8    Choice of Law: This Agreement is governed by and will be
construed in accordance with the laws of Colorado. 
 10.9    Dispute Resolution. In the event of any dispute
arising out of or relating to this Agreement, the affected party shall promptly provide notice to the other party, and the parties shall attempt in good faith to resolve the matter. 

 

	 	(a)	 Any disputes not so resolved shall be referred to the Principal Technology Transfer Officer for the University
and to Licensee’s Senior Executives with settlement authority, who shall meet at a mutually acceptable time and location within 30 days of the Notice Date and shall attempt to negotiate a settlement. 

 

	 	(b)	 If the Senior Executives fail to meet within 30 days of the Notice Date, or if the matter remains unresolved
for a period of 60 days after the Notice Date, Licensee hereby irrevocably submits to the jurisdiction of a court of competent jurisdiction in Colorado, and, by execution and delivery of this Agreement, Licensee (i) accepts, generally and
unconditionally, the jurisdiction of this court and any related appellate court, and (ii) irrevocably waives any objection it may now or hereafter have as to the venue of any such suit, action or proceeding brought in the court or that the
court is an inconvenient forum. 

 10.10 Merger and Modification of Agreement. The terms and provisions contained
in this Agreement constitute the entire agreement between the parties and supersede all previous communications, representations, agreements or understandings, either oral or written, between the parties with respect to the subject matter, and no
agreement or understanding varying or extending this Agreement will be binding upon either party to this Agreement, unless in a written amendment signed by duly authorized officers or representatives of the respective parties, and the provisions of
this Agreement not specifically amended thereby remain in full force and effect according to their terms. 
 10.11 Severability. The
provisions and clauses of this Agreement are severable, and in the event that any provision or clause is determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability will not in any way affect
the validity or enforceability of the remaining provisions and clauses. 
 10.12 Scope. This Agreement does not establish a joint
venture, agency or partnership between the parties, nor create an employer - employee relationship. 

  

					
	Non-Exclusive License Agreement	  	Page 12 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 10.13 Preservation of Immunity. Nothing in this Agreement is intended or should
be construed as a waiver, either express or implied, of any of the immunities, rights, benefits, defenses or protections provided to the University under governmental or sovereign immunity laws from time to time applicable to the University,
including, without limitation, the Colorado Governmental Immunity Act (C.R.S. § 24-10-101, et seq.) and the Eleventh Amendment to the United States Constitution.

 10.14 Headings. The headings are included for convenience only and may not be used to construe this Agreement. 

10.15 Survival. The provisions of Articles 3 Economic Consideration; 5 Confidential Information; 8 Warranties, Indemnifications,
and Insurance; 10.4 Use of Names and Marks; 10.8 Choice of Law; 10.13 Preservation of Immunity; 10.15 Survival and any other provision of this Agreement that by its nature is intended to survive, will survive any termination or expiration of this
Agreement. 
 (signatures follow on the next page) 

  

					
	Non-Exclusive License Agreement	  	Page 13 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 To evidence the parties’ agreement to this Agreement, the parties have executed it in duplicate and
delivered it on the date stated in the Preamble. 
  

			
	UNIVERSITY
		
	By:	 	                                     
                                         
  
	Kim Muller, Director
	CU Innovations
	University of Colorado Denver
	12635 E. Montview Blvd, Suite 270
	Aurora, CO 80045

  

			
	LICENSEE
		
	By:	 	 /s/ Joseph H. Gardner 

	Title:	 	Joseph H. Gardner
	President & CEO
	Aerpio Therapeutics, Inc.
	9987 Carver Road, Suite 420
	Cincinnati, OH 45242

  

					
	Non-Exclusive License Agreement	  	Page 14 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 To evidence the parties’ agreement to this Agreement, the parties have executed it in duplicate and
delivered it on the date stated in the Preamble. 
  

			
	UNIVERSITY
		
	By:	 	 /s/ Kimberly Muller

	Kim Muller, Director
	CU Innovations
	University of Colorado Denver
	12635 E. Montview Blvd. Suite 270
	Aurora, CO 80045

  

			
	LICENSEE
		
	By:	 	 Kimberly Muller

	Title:	 	Director of CU Innovations

  

					
	Non-Exclusive License Agreement	  	Page 14 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 APPENDIX A: SPECIFIC TERMS AND CONDITIONS 

 

	1.	 Licensed Patents: 

 

	 	(a)	 The Licensed Patents are as follows: 

 

									
	 Internal ID
	  	 Country
	  	 Serial No/Patent No
	  	 Title
	  	 Inventor

					
	CU2065H	  	US	  	 US 8,962,530 issued Feb. 24, 2015
 from
US Appl. No. 12/666,438
	  	Inflammatory Bowel Disease Therapies	  	Sean Colgan
					
	CU2065H	  	PCT	  	PCT/US2008/007962/ June 26, 2008	  	Inflammatory Bowel Disease Therapies	  	Sean Colgan
					
	CU2065H	  	US PPA	  	US Provisional Application 60/946,537	  	Inflammatory Bowel Disease Therapies	  	Sean Colgan

  

	 	(b)	 Field of Use: All. 

  

	 	(c)	 Territory: Worldwide. 

 

	2.	 Financial Conditions: 

[***] 

  

					
	Non-Exclusive License Agreement	  	Page 15 of 16	  	CU Case Number CU2065H

 Subject to FRE 408 

 

 [***] 

  

					
	Non-Exclusive License Agreement	  	Page 16 of 16	  	CU Case Number CU2065H

 LICENSE AGREEMENT 

EXHIBIT G 
 ASSIGNED
MANUFACTURING AGREEMENTS 
 [***] 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 SCHEDULE 9.1(a) 

For purposes of the last paragraph of Section 9.1: 
 [***]

 SCHEDULE 9.1(b) 
 For purposes
of the last paragraph of Section 9.1: 
 [***] 
  

 

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions.EX-10.19

 Exhibit 10.19 

Gossamer Bio, Inc. 
 3013 Science
Park Road, Suite 200, 
 San Diego, CA 92121 

July 20, 2018 
 HH Goss Holdings LLC 

Suite 2202, 22nd Floor 
 Two International Finance Centre 

8 Finance Street 
 Central, Hong Kong 

Attention: Michael Yi / Ting Jia 
 Email:
myi@hillhousecap.com; 
 ting.jia@hhresearch.com 
 With a copy
to: Adam Hornung 
 Email: Legal@hillhousecap.com 
 Re: Board
Designation Right 
 To Whom it May Concern: 

This letter agreement (this “Letter Agreement”) is made and entered into by and between Gossamer Bio, Inc., a Delaware
corporation (the “Company”), and HH Goss Holdings LLC (together with its affiliates, “Hillhouse”). Reference is hereby made to the Series B Preferred Stock Purchase Agreement (the “Purchase
Agreement”), dated on or about the date hereof, by and among the Company, Hillhouse and certain other purchasers listed from time to time on Schedule A to the Purchase Agreement, pursuant to which Hillhouse is purchasing shares (the
“Shares”) of the Company’s Series B Preferred Stock, $0.0001 par value per share. In connection with the purchase of the Shares by Hillhouse, the parties hereto agree as follows: 

1.    Certain Definitions. As used in this Agreement, the following terms shall have the following
respective meanings: 
 “Asthma Data Read-Out” shall mean the first
public data read-out of interim results from the GB001 Phase 2 clinical trial. 

“Board” shall mean the Board of Directors of the Company; 

“Effective Date” “shall mean the date of the closing of the IPO; 

“IPO” shall mean the initial public offering of shares of the Company’s common stock; and 

“Necessary Action” shall mean using best efforts, subject to applicable law and listing standards, to cause
such result that are within the power of the Company, including (i) causing members of the Board, subject to any fiduciary duties that such members may have as directors of the Company, to act in a certain manner, including causing members of
the Board or any nominating or similar committee of the Board to recommend to the stockholders of the Company the appointment of any Hillhouse Designee (as defined in Section 2 of this Letter Agreement) as provided by this
Agreement and to not withdraw or adversely modify such recommendation, (ii) executing agreements and instruments consistent with the terms hereof and refraining from taking any action that would reasonably be expected to adversely affect the
election of the Hillhouse Designee, (iii) making, or causing to be made, with governmental, administrative or regulatory authorities, all filings, 

 
registrations or similar actions that are required to achieve such result, and (iv) soliciting proxies and votes from the Company’s stockholders in favor of such recommendation. 

2.    Board Designation Right. From the Effective Date until the termination of this Letter
Agreement, the Company shall take all Necessary Action to designate one (1) individual designated by Hillhouse from time to time (including any replacement thereof, the “Hillhouse Designee”) to the Board; provided that
if at any time prior to the Effective Date, Hillhouse ceases to beneficially own at least 20% of the Shares issued to it under the Purchase Agreement, this Agreement shall not become effective and shall be of no further force or effect. If the
Company adopts a classified Board, the Company shall take all Necessary Action to cause the Hillhouse Designee to be part of the class with the longest remaining term. In the event that the Hillhouse Designee shall cease to serve as a director for
any reason, the Company shall take all Necessary Action to ensure that the vacancy resulting therefrom is not filled until Hillhouse has designated a replacement and the Company shall take all Necessary Action to cause the vacancy to be filled by
any replacement Hillhouse Designee as soon as practicable following Hillhouse’s designation of a replacement pursuant to the above provisions. The Company shall take all Necessary Action to appoint the Hillhouse Designee to any committee of the
Board that Hillhouse requests, provided that the Hillhouse Designee shall be a director and shall be eligible to serve on such committee under applicable law or listing standard. 

3.    Transfer of Rights. None of the rights or obligations in this Letter Agreement may be
transferred or assigned by either party hereto without the prior written consent of the other party. 

4.    Termination. If this Letter Agreement is not earlier terminated pursuant to
Section 2 hereof, this Letter Agreement shall terminate and be of no further force or effect at such time as Hillhouse ceases to beneficially own at least 5% of the outstanding voting stock of the Company, or upon the later
of (i) eighteen (18) months following the Effective Date or (2) six (6) months following the date of the Asthma Data Read-Out. 

5.    Governing Law. This Letter Agreement shall be governed by and construed in accordance with
the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other
than the State of Delaware. 
 6.    Counterparts. This Letter Agreement may be executed in one
or more counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which together shall be deemed to constitute one and the same instrument. 

7.    Amendments and Waivers. This Letter Agreement may be amended and the observance of any provision
herein may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of both parties hereto. 

8.    Entire Agreement. This Letter Agreement constitutes the entire agreement among the parties
with respect to the subject matter hereof and supersedes all prior agreement and understandings, both written and oral, among the parties with respect to the subject matter hereof. 

[Remainder of page intentionally left blank] 

 If you agree with the terms of this Letter Agreement, kindly countersign below. 

Regards, 
  

			
	 Gossamer Bio, Inc.

		
	By:	 	/s/ Faheem Hasnain

			
	Name:	 	Faheem Hasnain

			
	Its:	 	Chief Executive Officer

 ACKNOWLEDGED, ACCEPTED AND AGREED: 
  

			
	HH Goss Holdings LLC
		
	By:	 	/s/ Colm O’Connell

			
	Name:	 	Colm O’Connell
	Its:	 	Authorized Signatory
	Dated:	 	July 20, 2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]